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A B S T R A C T
Background
Standard treatment for deep vein thrombosis aims to reduce immediate complications. Use of thrombolysis or clot dissolving drugs
could reduce the long-term complications of post-thrombotic syndrome (PTS) including pain, swelling, skin discolouration, or venous
ulceration in the affected leg. This is the third update of a review first published in 2004.
Objectives
To assess the effects of thrombolytic therapy and anticoagulation compared to anticoagulation alone for the management of people
with acute deep vein thrombosis (DVT) of the lower limb as determined by the effects on pulmonary embolism, recurrent venous
thromboembolism, major bleeding, post-thrombotic complications, venous patency and venous function.
Search methods
For this update the Cochrane Vascular Information Specialist (CIS) searched the Specialised Register (February 2016). In addition the
CIS searched the Cochrane Register of Studies (CENTRAL (2016, Issue 1)). Trial registries were searched for details of ongoing or
unpublished studies.
Selection criteria
Randomised controlled trials (RCTs) examining thrombolysis and anticoagulation versus anticoagulation for acute DVT were consid-
ered.
Data collection and analysis
For this update (2016), LW and CB selected trials, extracted data independently, and sought advice from MPA where necessary.
We assessed study quality with the Cochrane risk of bias tool. For dichotomous outcomes, we calculated the risk ratio (RR) and
corresponding 95% confidence interval (CI). Data were pooled using a fixed-effect model unless significant heterogeneity was identified
in which case a random-effects model was used. GRADE was used to assess the overall quality of the evidence supporting the outcomes
assessed in this review.
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Main results
Seventeen RCTs with 1103 participants were included. These studies differed in the both thrombolytic agent used and in the technique
used to deliver it. Systemic, loco-regional and catheter-directed thrombolysis (CDT) were all included. Fourteen studies were rated as
low risk of bias and three studies were rated as high risk of bias. We combined the results as any (all) thrombolysis compared to standard
anticoagulation. Complete clot lysis occurred significantly more often in the treatment group at early follow-up (RR 4.91; 95% CI 1.66
to 14.53, P = 0.004) and at intermediate follow-up (RR 2.44; 95% CI 1.40 to 4.27, P = 0.002; moderate quality evidence). A similar
effect was seen for any degree of improvement in venous patency. Up to five years after treatment significantly less PTS occurred in
those receiving thrombolysis (RR 0.66, 95% CI 0.53 to 0.81; P < 0.0001; moderate quality evidence). This reduction in PTS was still
observed at late follow-up (beyond five years), in two studies (RR 0.58, 95% CI 0.45 to 0.77; P < 0.0001; moderate quality evidence).
Leg ulceration was reduced although the data were limited by small numbers (RR 0.87; 95% CI 0.16 to 4.73, P = 0.87). Those receiving
thrombolysis had increased bleeding complications (RR 2.23; 95% CI 1.41 to 3.52, P = 0.0006; moderate quality evidence). Three
strokes occurred in the treatment group, all in trials conducted pre-1990, and none in the control group. There was no significant effect
on mortality detected at either early or intermediate follow-up. Data on the occurrence of pulmonary embolism (PE) and recurrent
DVT were inconclusive. Systemic thrombolysis and CDT had similar levels of effectiveness. Studies of CDT included two trials in
femoral and iliofemoral DVT, and results from these are consistent with those from trials of systemic thrombolysis in DVT at other
levels of occlusion.
Authors’ conclusions
Thrombolysis increases the patency of veins and reduces the incidence of PTS following proximal DVT by a third. Evidence suggests
that systemic administration and CDT have similar effectiveness. Strict eligibility criteria appears to improve safety in recent studies
and may be necessary to reduce the risk of bleeding complications. This may limit the applicability of this treatment. In those who are
treated there is a small increased risk of bleeding. Using GRADE assessment, the evidence was judged to be of moderate quality due to
many trials having low numbers of participants. However, the results across studies were consistent and we have reasonable confidence
in these results.
P L A I N L A N G U A G E S U M M A R Y
Thrombolysis for treatment of acute deep vein thrombosis
Background
Deep vein thrombosis (DVT) occurs when a blood clot forms in a leg vein. The clot can break up and move to the lungs, leading
to a potentially serious blockage in blood flow (pulmonary embolism or PE). Because of the damage to the leg vein, post-thrombotic
syndrome (PTS) may develop any time over the next couple of years. Symptoms include leg pain, swelling, skin pigmentation and leg
ulcers, leading to loss of mobility. Anticoagulants are the standard treatment for DVT or a clot in a calf vein. These thin the blood to
reduce further clots from forming and prevent PE; yet PTS can still develop. Thrombolysis breaks down the blood clot. For DVT, drugs
such as streptokinase, urokinase and tissue plasminogen activator are infused into a vein in the arm or foot or, in some cases, directly
at the site of the clot using a catheter and X-ray control. Bleeding complications, stroke or intracerebral haemorrhage are potential
harmful events for both treatments.
Study characteristics and key results
The review results are based on 17 controlled trials that randomised a total of 1103 people with acute DVT (within 21 days of onset of
symptoms) to receive thrombolysis or anticoagulant treatment. Trials were carried out principally in the USA, Scandinavia, Germany
and the UK. All trials included men and women ranging in age from 18 to 75 years with a preponderance of older adults.
The present review (current until February 2016) showed that thrombolysis may have advantages over standard anticoagulation
treatment. Thrombolysis effectively dissolved the clot so that complete clot breakdown occurred more often with thrombolysis than
with standard anticoagulant therapy. Blood flow in the affected vein (venous patency) was also better maintained. Three trials (306
participants) continued for over sixmonths and found that fewer people developed PTSwhen treated with thrombolysis, 45% compared
with 66% in the standard anticoagulation treatment group. Two trials (211 participants) which continued for over five years also showed
that fewer people developed PTS when treated with thrombolysis.
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Those receiving thrombolysis had more bleeding complications than with standard anticoagulation (10% versus 8%). Most bleeding
episodes and deaths occurred in the older studies. Use of strict eligibility criteria appears to have improved the safety of this treatment,
which is effective delivered directly to the clot by catheter or via bloodstream from another vein.
Qualitity of the evidence
Using GRADE assessment, the evidence was judged to be of moderate quality due to many trials having low numbers of participants.
However, the results across studies were consistent and we have reasonable confidence in these results.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Treatment with any thrombolysis for acute DVT
Patient or population: pat ients diagnosed with acute DVT
Setting: hospital
Intervention: any thrombolysis
Comparison: control ant i-coagulat ion
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with control Risk with any throm-
bolysis
Complete clot lysis (in-
termediate, 6 months
to under 5 years af ter
treatment)
Study populat ion RR 2.44 (1.4 to 4.27) 630
(7 RCTs)
⊕⊕⊕©
MODERATE 1
78 (of 240) pa-
t ients treated with
standard ant icoagula-
t ion had complete clot
lysis compared to 198
(of 390) in the throm-
bolysis group
325 per 1000 793 per 1000 (455 to
1000)
Bleeding (early, up to 1
month af ter treatment)
Study populat ion RR 2.23
(1.41 to 3.52)
1103
(17 RCTs)
⊕⊕⊕©
MODERATE 1
Although 17 studies
reported on bleeding,
these were small stud-
ies43 per 1000 96 per 1000 (61 to 152)
Post-thrombotic syn-
drome (intermediate, 6
months to under 5 years
af ter treatment)
Study populat ion RR 0.66
(0.53 to 0.81)
306
(3 RCTs)
⊕⊕⊕©
MODERATE 1
96 (of 146) pat ients
treated with standard
ant icoagulat ion devel-
oped PTS compared to
72 (of 160) treated with
thrombolysis
658 per 1000 434 per 1000 (348 to
533)
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Post-thrombotic syn-
drome (late, 5 year fol-
low-up af ter treatment)
Study populat ion RR 0.58
(0.45 to 0.77)
211
(2 RCTs)
⊕⊕⊕©
MODERATE 1
72 (of 107) pat ients
treated with standard
ant icoagulat ion devel-
oped PTS compared to
41 (of 104) treated with
thrombolysis
673 per 1000 390 per 1000 (303 to
518)
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; DVT: deep vein thrombosis; PTS: post-thrombotic syndrome RCT : randomised controlled trial; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded by one level as the number of part icipants in each study is small
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B A C K G R O U N D
Description of the condition
Deep vein thrombosis (DVT) is a major health problem with be-
tween 2.5% to 5% of the population affected at some time in
their lives (Browse 1999; White 2006). Its main complications are
pulmonary embolism (PE) in the short term and post-thrombotic
syndrome (PTS) in the long term. Standard treatment is with an-
ticoagulation (thinning the blood to reduce formation of further
clots) and is aimed mainly at the prevention of PE and recurrent
DVT (Kearon 2016; NICE 2012). Despite treatment, over 50%
of patientsmay suffer post-thrombotic symptoms in the long term,
manifested by some degree of pain, swelling, skin pigmentation
or venous ulceration of the affected leg (Kahn 2006; Schulman
2006). This usually becomes apparent in the first two years after the
thrombotic event (Brandjes 1997; Kahn 2004; Kahn 2008). Most
studies report eventual venous ulceration in at least 6% of DVT
patients despite treatment with compression bandaging (Johnson
1995; Schulman 2006). The prevalence of venous ulcers in the
general population is around 1 in 1000, and between 40% to 50%
of patients with venous ulcers have evidence of post-thrombotic
damage (Browse 1999; Kahn 2004). Complications including ve-
nous ulcers may result in significant disability and may be difficult
to manage in both the community and secondary care. Because
complications develop after hospital admission, there is a low level
of awareness of these complications amongst the clinicians who
dealt with the acute admission.
Description of the intervention
Thrombolytic drugs act to dissolve blood clots by activating plas-
minogen. This forms an enzyme called plasmin that breaks links
between the fibrin molecules, which make up blood clots. The
drugs can be administered systemically through a peripheral vein,
loco-regionally via a vein close to the clot or directly via a catheter
to the occluding thrombus. The latter method more directly tar-
gets plasminogen within the clot and is less affected by potential
inhibitors in the circulation.
How the intervention might work
Dissolving the thrombus in the acute phase may reduce the risk
of more permanent damage to the structure and function of the
vein, in particular venous valvular function, thus lowering the risk
of post-thrombotic complications in the long term.
Why it is important to do this review
This systematic review draws together previous comparative trials
of thrombolysis and anticoagulation to reassess the advantages
and disadvantages of thrombolytic therapy in the context of acute
lower limb DVT and to identify areas for future research. This
systematic review is an update of a previously published Cochrane
review (Armon 2000;Watson 2004;Watson 2010;Watson 2014).
O B J E C T I V E S
To assess the effects of thrombolytic therapy and anticoagulation
compared to anticoagulation alone for the management of people
with acute DVT of the lower limb as determined by the effects
on clot lysis, bleeding and post thrombotic syndrome and other
relevant outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised trials of thrombolysis and anticoagulation versus
anticoagulation for acute lower limb DVT were considered. Any
method of randomisation was eligible, and differences in qual-
ity were taken into account in the analysis. Trials that were not
analysed on an intention-to-treat basis were included provided all
randomised participants were accounted for.
Types of participants
Trials of participants with acute DVT, defined as onset of symp-
toms within seven days and confirmed by objective testing with,
for example, venography or duplex ultrasonography, were consid-
ered.Trials includingparticipantswith chronic or recurrent venous
thrombosis were excluded, as were those with participants com-
mencing treatment after a maximum of 21 days from the onset of
symptoms. Trials including participants with arm vein thrombosis
were included in the update when the majority of cases affected
the lower limb.
Types of interventions
Trials with the use of any thrombolytic agent were included, the
principal ones being streptokinase, urokinase and tissue plasmino-
gen activator (tPA); other agents were included if used for the
treatment of acute DVT. All routes of drug lysis administration
were considered as were different dosing regimens of lytic agents.
This included systemic and catheter-directed thrombolysis (CDT)
methods.
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Types of outcome measures
Outcomes were classified into early (up to one month); interme-
diate (after six months to five years) or late (more than five years)
from time of intervention (see Included studies). When data were
reported between one and six months, we planned to discuss and
reassess the definition of our time points as required.
Primary outcomes
The following primary outcomes were included:
• Any improvement in venous patency (assessed by objective
measures such as venography, where pre- and post-comparative
data on the degree of restoration of the lumen were available);
• Complete clot lysis (defined as achievement of full patency
of the affected vein, or complete dissolution of the clot, by
objective measures);
• Bleeding complications excluding stroke or intracerebral
haemorrhage (defined as bleeding causing treatment to be
stopped, requiring transfusion or surgery, or causing chronic or
fatal sequelae);
• Stroke and in particular haemorrhagic stroke (preferably
documented by objective means such as a computerised
tomography scan or autopsy);
• PTS;
• Venous ulceration rates; and
• Mortality.
Secondary outcomes
Secondary outcomes included:
• Recurrent DVT;
• PE;
• Venous function (assessed by duplex ultrasound or other
objective means such as foot volumetry or ambulatory venous
pressure measurements);
• Quality of life (QoL); and
• Cost comparisons.
Search methods for identification of studies
Electronic searches
For this update the Cochrane Vascular Information Specialist
(CIS) searched the following databases for relevant trials (February
2016):
• The Cochrane Vascular Specialised Register; and
• The Cochrane Central Register of Controlled Trials
(CENTRAL (2016, Issue 1)) via The Cochrane Register of
Studies Online.
There were no restrictions on language. See Appendix 1 for details
of the search strategy used to search CENTRAL.
The Specialised Register is maintained by the CIS and is con-
structed from weekly electronic searches of MEDLINE, EM-
BASE, CINAHL, AMED, and through handsearching relevant
journals. The full list of the databases, journals and conference
proceedings which have been searched, as well as the search
strategies used are described in the Specialised Register section
of the Cochrane Vascular module in the Cochrane Library (
www.cochranelibrary.com).
The CIS searched the following trial registries for details of on-
going and unpublished studies using the terms ’thrombosis AND
thrombolysis’ (February 2016):
• ClinicalTrials.gov (www.clinicaltrials.gov);
• World Health Organization International Clinical Trials
Registry Platform (www.who.int/trialsearch); and
• ISRCTN Register (www.isrctn.com/).
Searching other resources
The reference lists of articles retrieved by electronic searches were
searched for additional citations.
Data collection and analysis
Data were collected from the original papers and authors were
contacted for clarification where necessary.
Selection of studies
LW and CB identified possible trials.
Data extraction and management
Data were collected using pro formas designed by Cochrane Vas-
cular. For this 2016 update, LW and CB independently completed
data extraction. Authors of ongoing trials were contacted to check
for available data but no response was received.
Assessment of risk of bias in included studies
Study quality was independently assessed by two review authors
(LW and CB, or MPA and CB) using forms designed according
to Cochrane and Cochrane Vascular guidelines and the Cochrane
risk of bias tool (Higgins 2011). Any disagreements were resolved
by discussion.
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Measures of treatment effect
Statistical analyses were performed according to the statistical
guidelines for review authors provided by Cochrane Vascular. If
appropriate, for each dichotomous outcome we calculated a sum-
mary statistic using the risk ratio (RR) and corresponding 95%
confidence interval (CI).
Unit of analysis issues
Individual participants were the unit of analysis. If appropriate,
the control groups in the multiple arm trials were divided up to
avoid double counting in the meta-analysis.
Dealing with missing data
Intention-to-treat analysis was conducted where possible. Any
missing statistics were recalculated from original data where avail-
able. Authors were contacted to request data where it was not pos-
sible to identify specific event numbers from the data reported.
Assessment of heterogeneity
Heterogeneity was assessed clinically from descriptions of studies,
visually from forest plots and statistically using the Chi2 test. If P
< 0.05 a random-effects model was used, otherwise a fixed-effect
model was reported. We also considered heterogeneity by clini-
cal judgements of differences in participant populations, interven-
tions and outcome assessments.
Assessment of reporting biases
Reporting bias was assessed through a review of the studies iden-
tified and funnel plots were considered if relevant.
Data synthesis
We pooled studies for meta-analysis when the interventions, pa-
tient groups, outcomemeasures and timing of outcome assessment
were sufficiently similar (determined by consensus). The pooled
RR and corresponding 95% CI were calculated for dichotomous
outcomes. A fixed-effect model was used unless statistical hetero-
geneity was identified (as described above), in which case a ran-
dom-effects model was used.
Subgroup analysis and investigation of heterogeneity
Trials were analysed together and in subgroups according to route
of administration. Other sources of heterogeneity such as partic-
ipant selection, type of DVT, drug or dose were commented on
where relevant.
Sensitivity analysis
Sensitivity analysis included the exclusion of studies deemed to be
at high risk of bias from pooled analyses to see whether this would
influence the results.
Summary of findings
We created ’Summary of findings’ tables using the GRADEpro
software. This summarised the evidence comparing thromboly-
sis to standard anticoagulation for study populations consisting
of patients with acute DVT (Summary of findings for the main
comparison); and comparing CDT versus standard anticoagula-
tion for DVT (Summary of findings 2). The most important
and clinically relevant outcomes (both desirable and undesirable)
that were thought to be essential for decision-making were the
outcomes complete clot lysis, bleeding and post-thrombotic syn-
drome. Assumed control intervention risks were calculated by the
mean number of events in the control groups of the selected studies
for each outcome. The system developed by the Grades of Recom-
mendation, Assessment, Development and Evaluation Working
Group (GRADE working group) was used for grading the quality
of evidence as high, moderate, low and very low, based on within-
study risk of bias, inconsistency, directness of evidence, impreci-
sion, and publication bias (Atkins 2004).
R E S U L T S
Description of studies
Results of the search
No new included studies were identified for this 2016 update (See
Figure 1). Nine additional publications from the Cavent study
(Enden 2011) were identified, one of which reported five year
follow-up data (Haig 2016). Seven new studies were excluded
(Bashir 2014; Cakir 2014; Engelberger 2015; Patra 2014; Santiago
2014; Sui 2013; Zhang 2014), and two new ongoing studies were
identified (IRCT201108035625N3; NCT00970619).
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Figure 1. Study flow diagram.
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Included studies
In total 17 trials were included, with 1103 participants (Arneson
1978; Common 1976; Elliot 1979; Elsharawy 2002; Enden 2011;
Goldhaber 1990; Goldhaber 1996; Kakkar 1969; Kiil 1981;
Marder 1977; Schulman 1986; Schweizer 1998; Schweizer 2000;
Tsapogas 1973; Turpie 1990; Ugurlu 2002; Verhaeghe 1989).
Studies were carried out from 1969 to 2009. A cut-off of 21 days
from onset of symptoms was used, therefore a small number of
studies excluded on this basis from the original review were in-
cluded.
Participants
Trials were carried out principally in the USA, Scandinavia, Ger-
many and the UK. All trials included men and women and the age
range was 18 to 75 years with a preponderance of older adults. The
participants had diverse underlying causes for developing DVT,
and varying degrees of level and extent of occlusion. The trial by
Elsharawy 2002 was conducted in DVT affecting femoral and il-
iofemoral veins and Enden 2011 included pelvic, femoral and il-
iofemoral veins, whereas other trials included thrombosis affect-
ing different combinations of levels, including popliteal. The only
study to include calf vein thrombosis only was Schulman 1986.
See Table 1, ’Level of affected leg veins in included studies’.
Inclusion criteria
Inclusion criteria have become more restrictive over time. In the
earliest study by Kakkar 1969, there were only four contra-indica-
tions: surgery within three days, an unhealed wound, peptic ulcer
and hypertension. By the time of Schweizer 2000, a more compre-
hensive list of contra-indications had been developed including:
surgery or head trauma within the previous three months, malig-
nancy, renal and hepatic dysfunction, and bleeding dysfunction,
which in later studies reduces the proportion of eligible partici-
pants.
Interventions
Interventions included systemic, loco-regional andCDT. Systemic
and loco-regional techniques differ only in the veins used to de-
liver an infusion: the arm or foot respectively. CDT is a more in-
vasive procedure in which a catheter is inserted into the popliteal
vein behind the knee using X-ray control. The thrombolytic agent
is infused through the catheter into the blood clot itself and the
position of the catheter is altered according to the progress made
in lysing the blood clot. The majority of trials assessed systemic
thrombolysis, with streptokinase the most common agent used.
The dose used varied: Schulman 1986 used a low-dose regime of
systemic streptokinase, Tsapogas 1973 used loco-regional strep-
tokinase and Elsharawy 2002 used catheter-directed streptokinase
with frequent radiological assessment, a technique used again in
Enden 2011.
Goldhaber 1990, Turpie 1990 and Verhaeghe 1989 used systemic
tPA. While doses of tPA varied, there was no obvious cut-off for
high or low doses. Goldhaber 1996 randomised two regimes of
tPA, with and without heparin, compared to heparin alone. The
two treatment arms were combined for the purposes of this re-
view. Schweizer 1998 had two treatment arms, loco-regional tPA
and urokinase; and Schweizer 2000 had four treatment arms: sys-
temic streptokinase, systemic urokinase, loco-regional urokinase
and loco-regional tPA. Kiil 1981 used low-dose systemic uroki-
nase.
Co-treatments
Monitoring regimes for heparinisation varied, and length of anti-
coagulation after the initial phase may be limited to a few months
or continued for over a year. In some trials, especially the more re-
cent ones, the use of compression bandages and elevation were re-
ported; and for longer follow-up, some participants were required
to use compression stockings with rigorous ascertainment of com-
pliance with the continued treatment.
Size
Nine studies had less than 50 participants (Arneson 1978;
Elsharawy 2002; Goldhaber 1996; Kakkar 1969; Kiil 1981;
Marder 1977; Schulman 1986; Tsapogas 1973; Verhaeghe 1989),
and two studies had more than 100 participants (Enden 2011;
Schweizer 2000). Most studies therefore lacked power to detect
statistically significant effects. A power calculation was described
in three studies (Elsharawy 2002; Enden 2011; Schweizer 2000).
Schweizer 2000 was the largest trial with 250 participants.
Outcomes
One trial (Verhaeghe 1989), reported results for randomised par-
ticipants together with non-randomised participants. Some stud-
ies reported outcomes using scales which could not be combined
(Marder 1977). Removal of the clot was reported using various
categorisations. Both complete clot dissolution or lysis, indicating
that the venous patency was 100% restored, and any degree of
venographic improvement in patency were reported in this review
in order to capture as much information as possible. Tsapogas
1973 reported partial or complete clearance (75% to 100%), a
measure not used in any other study, and others reported partial
clearance (50% to 100%). One study reported on Qol and cost
comparisons (Enden 2011).
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Length of follow-up
All trials assessed outcomes in the period immediately after treat-
ment. This was usually at one week, although the range was 36
hours to one month. We collectively grouped these as early out-
comes. Intermediate outcomes have been classified as those deter-
mined after six months and under 5 years. No data were reported
between this early and intermediate phase (i.e. after one month
and before six months). Late outcomes were those reported 5 years
or more after the intervention. PTS was assessed between one and
six years. The longest follow-up (six years) was in the Arneson
1978 study. For this update (2016), late data (five year follow-up)
from Enden 2011 has been included.
Excluded studies
Seven additional trials were excluded for this 2016 update (Bashir
2014; Cakir 2014; Engelberger 2015; Patra 2014; Santiago 2014;
Sui 2013; Zhang 2014). Reasons for exclusion included not ran-
domised (Bashir 2014; Santiago 2014), did not compare throm-
bolysis with anticoagulant (Cakir 2014; Engelberger 2015; Sui
2013; Zhang 2014), and onset of symptoms beyond 21 days
(Patra 2014). Sixteen trials were previously excluded because they
did not meet the inclusion criteria. Four trials (Browse 1968;
Johansson 1979; Robertson 1967; Schweizer 1996) did not sat-
isfy the criteria for randomisation. In other cases, studies did not
include a comparison of thrombolysis versus anticoagulation, or
DVT was not confirmed objectively (Bieger 1976; Marini 1991;
Markevicius 2004; Pinto 1997; Silistreli 2004; Tibbutt 1974;
Tibbutt 1977; Zimmermann 1986). In three cases insufficient in-
formation was obtained despite attempts to contact the authors
(Ansell 1990; Persson 1977; Sas 1985). TORPEDO 2012 was ex-
cluded as only 33 out 90 participants received thrombolysis. See
the Characteristics of excluded studies table for further informa-
tion.
Ongoing Studies
Two new ongoing studies
were identified (IRCT201108035625N3; NCT00970619). See
Characteristics of ongoing studies for further details.We contacted
the study investigators of these to ask if any data were available
but we did not receive a response.
Risk of bias in included studies
The quality of reporting of the majority of trials was high, see
Figure 2 and Figure 3. See the Characteristics of included studies
table for detailed information. Minor protocol violations were re-
ported in several studies, and losses to follow-up were more com-
mon in the later phases.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Many studies reported random allocation from a randomnumbers
table or computer generated sequence (Arneson 1978; Elsharawy
2002; Enden 2011; Goldhaber 1990; Schulman 1986; Schweizer
1998; Tsapogas 1973; Ugurlu 2002; Verhaeghe 1989), although
sometimes this detail was lacking (Common 1976; Elliot 1979;
Goldhaber 1996; Kiil 1981;Marder 1977; Schweizer 2000; Turpie
1990; Verhaeghe 1989). Many older studies did not give details
on allocation concealment, and this remained a possible risk of
bias (Common 1976; Elliot 1979; Elsharawy 2002; Kiil 1981;
Marder 1977; Schweizer 1998; Schweizer 2000; Turpie 1990;
Ugurlu 2002; Verhaeghe 1989). Studies with good allocation con-
cealment also found significant effects. In some cases insufficient
detail was reported on whether envelopes were sequentially num-
bered, sealed or opaque (Common 1976; Elliot 1979; Goldhaber
1996; Schulman 1986; Tsapogas 1973).
Blinding
With the exception of Tsapogas (Tsapogas 1973), all studies
used blinding for the assessment of venograms. Turpie 1990 and
Verhaeghe 1989 used identical placebo infusions and therefore
were double blind. Where participants were not blinded to the
treatment group (Arneson 1978; Common 1976; Elliot 1979;
Elsharawy 2002; Enden 2011; Goldhaber 1990; Goldhaber 1996;
Kakkar 1969; Marder 1977; Schweizer 1998; Schweizer 2000;
Tsapogas 1973; Ugurlu 2002), an assessment was made that this
introduced a low risk of bias where the assessor was blinded and
using objective measures, which was the case in most studies
(Arneson 1978; Common 1976; Elliot 1979; Elsharawy 2002;
Enden 2011; Goldhaber 1990; Goldhaber 1996; Schulman 1986;
Schweizer 1998; Schweizer 2000; Turpie 1990; Ugurlu 2002;
Verhaeghe 1989). Blinding participants would be more difficult
with more interventional approaches. However, this lack of blind-
ing of participants may have introduced bias in the longer term
as participants in receipt of thrombolysis may be more likely to
have impressed upon them, or to heed advice given on, the im-
portance of complying with co-treatments such as compression
stockings. For example, compliance was higher in the treatment
group in Enden 2011. In Kakkar 1969 neither the participants
nor outcome assessors were blinded, and this study was therefore
judged to have a high risk of bias.
Incomplete outcome data
Most studies did not demonstrate any major differences in fol-
low-up between the treatment and control groups for the main
outcomes, in the early or intermediate follow-up periods. Marder
1977 was assessed as having high risk of bias for this category as it
was not possible to separate the data from the three patients who
were added non-randomly after randomisation took place.
Selective reporting
In some cases subgroups were reported that did not include all trial
participants, for example PTS in those with complete clot lysis,
but these were not included in the review. As results including
non-randomised participants were reported in Marder 1977, this
was judged as at high risk of bias. Duplicate reports of studies
were identified in the selection process and multiple sources were
searched, with no language restriction. A funnel plot was not used
as there were less than 10 studies reporting on the most relevant
outcomes measuring effect.
Other potential sources of bias
There were no other specific concerns about bias except forMarder
1977 who added three non-randomised participants to the study
post-randomisation.
Effects of interventions
See: Summary of findings for the main comparison Treatment
with any thrombolysis for acute deep vein thrombosis; Summary
of findings 2 Treatment with catheter directed thrombolysis for
acute deep venous thrombosis
Comparison 1. Any thrombolysis versus control
Seventeen studies were included for this comparison (Arneson
1978; Common 1976; Elliot 1979; Elsharawy 2002; Enden 2011;
Goldhaber 1990; Goldhaber 1996; Kakkar 1969; Kiil 1981;
Marder 1977; Schulman 1986; Schweizer 1998; Schweizer 2000;
Tsapogas 1973; Turpie 1990; Ugurlu 2002; Verhaeghe 1989).
Outcome 1: any improvement in venous patency (early)
Nine trials reported on improvements in venous patency defined
by a change in occlusion of the affected segment after treatment
(Arneson 1978; Common 1976; Elsharawy 2002; Goldhaber
1990; Goldhaber 1996; Kakkar 1969; Kiil 1981; Turpie 1990;
Ugurlu 2002). With all studies except Kiil 1981, improvement
was more marked in the treatment group. Out of a total of 610
participants, improvement was significantly more likely in those
receiving thrombolysis (RR 2.48; 95%CI 1.35 to 4.57, P = 0.004;
Analysis 1.1). Statistical heterogeneity was noted in the results and
a random-effects model was used. The study by Marder 1977,
which showed a difference inmean change from venograms, could
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not be included due to the reporting format used. A greater im-
provement was noted but for randomised participants this was
not reported to be significantly different. Similarly the Verhaeghe
1989 data could not be included in the meta-analysis.
Outcome 2: complete clot lysis (early)
Eight trials with 592 participants reported on the occurrence of
complete clot lysis (Common 1976; Elliot 1979; Elsharawy 2002;
Goldhaber 1990; Kakkar 1969; Schulman 1986; Schweizer 2000;
Ugurlu 2002). In all trials this was more likely in the treatment
group, although the extent of the effect varied and the results were
statistically heterogeneous. A random-effects model demonstrated
a significant improvement (RR 4.91; 95% CI 1.66 to 14.53, P =
0.004; Analysis 1.2).
Outcome 3: bleeding (early)
This category excluded cerebral bleeding and minor bleeds,
for example oozing from venepuncture sites and superficial
haematomas. All 17 trials reported on the occurrence of bleeding
episodes (Arneson 1978; Common 1976; Elliot 1979; Elsharawy
2002; Enden 2011; Goldhaber 1990; Goldhaber 1996; Kakkar
1969; Kiil 1981; Marder 1977; Schulman 1986; Schweizer 1998;
Schweizer 2000; Tsapogas 1973; Turpie 1990; Ugurlu 2002;
Verhaeghe 1989).While none of the studies individually showed a
statistically significant increase in bleeding, participants receiving
thrombolysis were significantly more likely than control partici-
pants to experience a bleeding complication. Nine per cent (62/
662) of patients in the thrombolysis group experienced a bleeding
complication compared to 4% (19/441) of patients in the stan-
dard anticoagulation group (RR 2.23; 95% CI 1.41 to 3.52, P =
0.0006; moderate quality evidence; Analysis 1.3), with a number
needed to treat for an additional harmful outcome (NNTH) of
17.
Outcome 4: stroke or intracerebral haemorrhage (early)
Three trials reported the occurrence of stroke or intracerebral
haemorrhage (Common 1976; Goldhaber 1990; Marder 1977).
All trials described bleeding complications, therefore the absence
of mention of any serious neurological complications or cerebral
bleeds was taken to indicate that none were detected.Out of a total
of 1103 participants three events occurred in the treatment group
(a rate of 0.3%) and none in the control group. The pooled RR
was 1.92 (95% CI 0.34 to 10.86) with wide uncertainty regarding
the true effect (Analysis 1.4).
Outcome 5: mortality (early)
Nine trials reported deaths occurring up to one month after treat-
ment (Arneson 1978; Common 1976; Elliot 1979; Elsharawy
2002; Kakkar 1969; Kiil 1981; Marder 1977; Schulman 1986;
Schweizer 2000); two trials reported that nodeaths occurred in this
period (Elsharawy 2002; Schweizer 2000). A total of five events
occurred in the treatment group and seven in the control group
out of a total 529 participants. The pooled RR was 0.76 (95%
CI 0.31 to 1.89; Analysis 1.5); however the wide CI indicated a
large degree of uncertainty around the true effect and there were
relatively few events.
Outcome 6: pulmonary embolus (PE) (early)
Six trials reported the occurrence of a PE in the early phase
(Arneson 1978; Elliot 1979; Elsharawy 2002; Kakkar 1969;
Schulman 1986; Schweizer 2000). One study noted the absence
of any PE (Schulman 1986). The diagnostic criteria used were
variable. With the exception of participants who died from PE
(one in the treatment group, two in the control group), transient
clinical symptoms often occurred but with no objective diagnos-
tic confirmation described. Where deaths were attributed to PE,
postmortem examinations were not mentioned. For this reason,
the results should be interpreted with caution. The RR was 1.00
(95% CI 0.33 to 3.05; Analysis 1.6).
Outcome 7: post-thrombotic syndrome (PTS) (intermediate
and late)
Three studies reported clinically assessed PTS at six months to 5
years (intermediate) (Elliot 1979; Enden 2011; Schweizer 1998),
excluding ulceration, in a format that could be combined, with a
total of 306 participants. Significantly less PTS occurred in those
participants receiving thrombolysis (45% incidence with RR 0.66,
95% CI 0.53 to 0.81; P < 0.0001; moderate quality evidence;
Analysis 1.7), with a number needed to treat for an additional
beneficial outcome (NNTB) of five. In the control group the in-
cidence was 96/146 (66%, ranging from 35% to 96% in different
trials, which may reflect definitions and adjunctive treatments).
Two studies with 211 participants (Arneson 1978; Enden 2011),
reported clinically assessed PTS at over five years (late); (RR 0.58,
95% CI 0.45 to 0.77; P < 0.0001; moderate quality evidence;
Analysis 1.8). In the control group the incidence was 72/107 and
in the thrombolysis group 41/104. The NNTB at late follow-up
was four.
Outcome 8: leg ulceration (intermediate and late)
Four studies described ulceration of the leg occurring more than
six months from trial entry (Elliot 1979; Enden 2011; Schulman
1986; Schweizer 1998). Three events occurred in the treatment
group and two in the control group out of 342 participants, giving
a RR 0.87 (95% CI 0.16 to 4.73; Analysis 1.9).This was not
statistically significant (P = 0.87).
Arneson 1978 reported at a mean of 6.5 years and so fell within
the definition of late ulceration. Events were more likely with late
follow-up, with 3/18 control participants experiencing ulceration
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after six years compared to 0/17 in the thrombolysis participants
(RR 0.15, 95% CI 0.01 to 2.72; P = 0.20; Analysis 1.10).
Outcome 9: complete clot lysis (intermediate and late)
Seven trials with a total of 630 participants reported clot lysis after
sixmonths and in all cases this wasmore likely in the groups treated
with thrombolysis (Common 1976; Elliot 1979; Elsharawy 2002;
Enden 2011; Schulman 1986; Schweizer 1998; Schweizer 2000).
This was statistically significant with a RR of 2.44; 95%CI 1.40 to
4.27; P = 0.002 using a random-effects model (moderate quality
evidence; Analysis 1.11).
Two trials with a total of 206 participants reported clot lysis at five
years and over (Arneson 1978; Enden 2011). Clot lysis was not
significantly more likely with thrombolysis at this time point (RR
3.25, 95% CI 0.17 to 62.63; Analysis 1.12).
Outcome 10: mortality (intermediate and late)
Two trials with a total of 289 participants reported mortality oc-
curring up to five years after treatment (Elliot 1979; Schweizer
2000). Elliot 1979 reported 4 deaths in each group. Most deaths
were unrelated to the clot or treatment but rather to underlying
conditions. The RR was 0.96 (95% CI 0.27 to 3.43; Analysis
1.13), however there was wide uncertainty around the true effect.
Two trials with a total of 230 participants reported mortality after
five years follow-up (Arneson 1978; Enden 2011). Seven deaths
occurred in the thrombolysis group and 12 in the control group
with a RR of 0.61 (95% CI 0.25 to 1.50; Analysis 1.14); again
with no significant difference detected.
Outcome 11: normal venous function (intermediate)
Three trials reported on presence of normal venous function
(Elsharawy 2002; Enden 2011; Schulman 1986). The RR was
2.18 (95% CI 0.86 to 5.54; Analysis 1.15) using a random-effects
model.
Outcome 12: recurrent venous thromboembolism
(DVT/VTE, intermediate and late)
One trial reported on recurrentDVT (Arneson 1978). Four events
occurred in the treatment group compared to three in the control
group. The RR was 1.41 (95% CI 0.37 to 5.40); the numbers
were too small to draw any firm conclusion. At five year follow-
up Enden 2011 showed a non-significant reduction in recurrent
VTE (RR 0.63, 95% CI 0.34 to 1.18; Analysis 4.14).
Outcome 13: quality of life
Only Enden 2011 has reported on this outcome (Enden 2013a;
Haig 2016). As this was a study using CDT, we have reported the
details within comparison four.
Outcome 14: cost comparisons
Only Enden 2011 has reported on this outcome (Enden 2013b).
As this was a study using CDT, we have reported the details within
comparison four.
We carried out sensitivity analyses for all outcomeswhere themeta-
analysis included trials judged to have any domain at high risk of
bias (Kakkar 1969;Marder 1977; Tsapogas 1973). To determine if
results were robust, analyses were repeated excluding these studies.
Forest plots and summary figures were visually assessed and for all
outcomes the results remained consistent.
Comparison 2. Systemic thrombolysis versus control
Fifteen trials compared systemic thrombolysis to control (Arneson
1978; Common 1976; Elliot 1979; Goldhaber 1990; Goldhaber
1996; Kakkar 1969; Kiil 1981; Marder 1977; Schulman 1986;
Schweizer 1998; Schweizer 2000; Tsapogas 1973; Turpie 1990;
Ugurlu 2002; Verhaeghe 1989).
Outcome 1: any improvement in venous patency (early)
Eight trials reported on this outcome and a significant improve-
ment in patency was demonstrated (Arneson 1978; Common
1976;Goldhaber 1990;Goldhaber 1996; Kakkar 1969; Kiil 1981;
Turpie 1990; Ugurlu 2002). The RR was 2.18 (95% CI 1.28 to
3.70, P = 0.004; Analysis 2.1) using a random-effects model.
Outcome 2: complete clot lysis (early)
Seven trials reported a significant improvement in clot lysis
(Common 1976; Elliot 1979; Goldhaber 1990; Kakkar 1969;
Schulman 1986; Schweizer 2000; Ugurlu 2002), with a RR of
4.37 (95% CI 1.4 to 13.61, P = 0.01; Analysis 2.2) using a ran-
dom-effects model.
Outcome 3: bleeding (early)
Fifteen trials reported on the occurrence of bleeding episodes
(Arneson 1978; Common 1976; Elliot 1979; Goldhaber 1990;
Goldhaber 1996; Kakkar 1969; Kiil 1981; Marder 1977;
Schulman1986; Schweizer 1998; Schweizer 2000;Tsapogas 1973;
Turpie 1990; Ugurlu 2002; Verhaeghe 1989). Bleeding complica-
tions were twice as likely in the thrombolysis group with a RR of
2.18 (95% CI 1.37 to 3.47, P = 0.001; Analysis 2.3).
Outcome 4: stroke or intracerebral haemorrhage (early)
Three trials reported the occurrence of stroke or intracerebral
haemorrhage (Common 1976; Goldhaber 1990; Marder 1977).
There were three events in the treatment group but this was not
statistically significant (RR 1.92, 95% CI 0.34 to 10.86, P = 0.46;
Analysis 2.4). All trials described bleeding complications, therefore
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the absence of mention of any serious neurological complications
or cerebral bleeds was taken to indicate that none were detected.
Outcome 5: mortality (early)
Eight trials reported deaths occurring up to one month after treat-
ment (Arneson 1978; Common 1976; Elliot 1979; Kakkar 1969;
Kiil 1981; Marder 1977; Schulman 1986; Schweizer 2000); one
trial reported that no deaths occurred in this period (Schweizer
2000). A total of five events occurred in the treatment group and
seven in the control group, out of a total of 394 participants. There
were relatively few events and this result was not statistically sig-
nificant (RR 0.76; 95% CI 0.31 to 1.89, P = 0.56; Analysis 2.5).
Outcome 6: pulmonary embolus (PE) (early)
Five trials reported occurrence of a PE in the early phase (Arneson
1978; Elliot 1979; Kakkar 1969; Schulman 1986; Schweizer
2000). There was an increase, affected by nine events in the
Schweizer 2000 trial, but this was not statistically significant (RR
1.73; 95% CI 0.55 to 5.40, P = 0.35; Analysis 2.6).
Outcome 7: post-thrombotic syndrome (PTS, intermediate
and late)
Two studies with 117 participants reported this outcome from six
months to under five years from treatment (Elliot 1979; Schweizer
1998) with a reduction of almost 50% in the treatment group (RR
0.56, 95% CI 0.30 to 1.03; Analysis 2.7).
Arneson 1978 reported at a late time point also with a reduction
of about 50% in the treatment group (RR 0.47, 95% CI 0.18 to
1.25; Analysis 2.8), but with a wide uncertainty around the true
effect. Only 35 participants were included in this study.
Outcome 8: leg ulceration (intermediate and late)
Three studies with a total of 153 participants described ulceration
of the leg occurring more than six months from trial entry (Elliot
1979; Schulman 1986; Schweizer 1998).There were similar events
between the two groups but the number of events was small (RR
0.87, 95% CI 0.16 to 4.73; P = 0.87; Analysis 2.9). Arneson 1978
described ulceration after five years with the three events all in the
control group (RR 0.15, 95% CI 0.01 to 2.72; P = 0.2; Analysis
2.10). Numbers are too small to draw conclusions.
Outcome 9: complete clot lysis (intermediate and late)
Five trials with a total of 300 participants reported effects on clot
lysis six months from treatment (Common 1976; Elliot 1979;
Schulman1986; Schweizer1998; Schweizer 2000).Complete lysis
was nearly two and a half times as likely in the treatment group
(RR 2.59, 95% CI 1.27 to 5.28; using a random-effects model P
= 0.009; Analysis 2.11).
Only Arneson 1978 reported late data and all patients with com-
plete clot lysis were within the treatment group (RR 3.25, 95%
CI 0.17 to 62.63; P = 0.05; Analysis 2.12). At this time point
numbers are too small to draw conclusions.
Outcome 10: mortality (intermediate and late)
Two studies with a total of 189 participants reported on this out-
come at sixmonths follow-up (Elliot 1979; Schweizer 2000).Only
Arneson 1978 (n = 42) reported mortality after five years. There
was no significant difference between the two groups (RR 0.96,
95%CI 0.27 to 3.43; Analysis 2.13) at intermediate or late follow-
up (RR 1.33, 95% CI 0.34 to 5.24; Analysis 2.14).
Outcome 11: normal venous function (intermediate)
This was only reported by Schulman 1986 (RR 1.04; 95% CI
0.59 to 1.83; Analysis 2.15).
Outcome 12: recurrent DVT (intermediate and late)
This was only reported by Arneson 1978 at late follow-up (RR
1.41; 95% CI 0.37 to 4.40; Analysis 2.16).
As for Comparison 1, we carried out sensitivity analyses for all out-
comes where the meta-analysis included trials judged to have any
domain at high risk of bias (Kakkar 1969;Marder 1977; Tsapogas
1973). To determine if the results were robust, analyses were re-
peated excluding these studies. Forest plots and summary figures
were visually assessed and for all outcomes the results remained
consistent.
Comparison 3. Loco-regional thrombolysis versus
control
Two trials compared loco-regional thrombolysis to control (
Schweizer 1998; Schweizer 2000).
Outcome 1: complete clot lysis (early)
This was reported by Schweizer 2000, who reported a marked
effect (RR 10; 95% CI 1.33 to 75.23).
Outcome 2: bleeding (early)
Both Schweizer 1998 and Schweizer 2000 reported on this out-
come. Based on three events, bleeding was more likely in the treat-
ment group (RR 4.0; 95% CI 0.46 to 34.75, P = 0.21).
Outcome 3: stroke or intracerebral haemorrhage (early)
No events occurred in either the Schweizer 1998 or Schweizer
2000 trials.
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Outcome 4: mortality (early)
No events occurred in the Schweizer 2000 trial and Schweizer
1998 did not report on this outcome.
Outcome 5: pulmonary embolus (PE) (early)
No events occurred in the Schweizer 2000 trial and Schweizer
1998 did not report on this outcome.
Outcome 6: post-thrombotic syndrome (PTS)
(intermediate)
This was reported by Schweizer 1998 only. A total of 11 partici-
pants in the treatment group and 17 in the control group, out of
a total of 44 participants, were reported to have PTS (RR 0.65;
95% CI 0.40 to 1.04).
Outcome 7: leg ulceration (intermediate)
This was reported by Schweizer 1998 only. One participant in
each group developed leg ulcers (RR 1.00; 95%CI 0.07 to 15.00).
Outcome 8: complete clot lysis (intermediate)
Both trials (Schweizer 1998; Schweizer 2000) demonstrated sig-
nificant improvement (RR 2.25; 95%CI 1.33 to 3.80, P = 0.002).
Outcome 9: mortality (intermediate)
Only Schweizer 2000 reported on this outcome. No events oc-
curred.
Comparison 4. Catheter-directed thrombolysis
versus control
Two trials compared CDT to control (Elsharawy 2002; Enden
2011).
Outcome 1: any improvement in venous patency (early)
This was reported only by Elsharawy 2002, with significant im-
provement in venous patency (RR 35.05; 95% CI 2.28 to 539.63;
P = 0.01; Analysis 4.1).
Outcome 2: complete clot lysis (early)
This was reported only by Elsharawy 2002, with significant im-
provement (RR 21.79; 95% CI 1.38 to 343; P = 0.03; Analysis
4.2).
Outcome 3: bleeding (early)
Both Enden 2011 and Elsharawy 2002 reported on this with a
total of 224 participants. Based on three events in the treatment
group (3%) and none in the control group, the RR was 7.69 (95%
CI 0.4 to 146.9; Analysis 4.3).
Outcome 4: stroke or intracerebral haemorrhage (early)
There were no events recorded by Elsharawy 2002 or Enden 2011.
Both trials described bleeding complications, therefore the absence
of mention of any serious neurological complications or cerebral
bleeds was taken to indicate that none were detected.
Outcome 5: mortality (early)
There were no events recorded by Elsharawy 2002 and Enden
2011 did not report events at this time point.
Outcome 6: pulmonary embolus (PE) (early)
There was one event in the control group (RR 0.32; 95% CI 0.01
to 7.26) from a total of 35 participants (Elsharawy 2002). Enden
2011 did not measure this outcome at this time point.
Outcome 7: post-thrombotic syndrome (PTS) (intermediate
and late)
Elsharawy 2002 did not report on this outcome. The RR of PTS
at six months was reported by Enden 2011 to be 0.93 (95% CI
0.61 to 1.42). At 24 months the number of events in both the
treatment and control groups had risen from 27 to 37 and 32 to
55 respectively; the RR was 0.74 (95% CI 0.55 to 1.00; P = 0.05;
Analysis 4.7), close to being statistically significant. At five year
late follow-up Enden 2011 reported that the number of events
in the treatment group remained at 37 and those in the control
group had risen to 63. The RR was 0.6 (95% CI 0.45 to 0.79; P
= 0.0003; Analysis 4.8).
Outcome 8: leg ulceration (intermediate)
There were no events reported by Enden 2011 and Elsharawy
2002 did not report on this outcome.
Outcome 9: complete clot lysis (intermediate and late)
Both Enden 2011 and Elsharawy 2002 reported on complete clot
lysis at the intermediate time point, with a total of 224 partici-
pants. Complete clot lysis was more likely in the treatment group
although the difference was not statistically significant using a
random-effects model (RR 2.52, 95% CI 0.52 to 12.17, P =
0.25; moderate quality evidence; Analysis 4.10). By late follow-up
Enden 2011 reported similar numbers of complete lysis (68/86
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and 61/86 in treatment and control respectively; RR 1.11, 95%
CI 0.94 to 1.33; Analysis 4.11).
Outcome 10: mortality (intermediate and late)
Elsharawy 2002 did not report on mortality and Enden 2011
reportedmortality after five years follow-up.Three deaths occurred
in the CDT group (3/90), compared to nine in the control group
(9/98; RR 0.36, 95% CI 0.10 to 1.30; Analysis 4.15).
Outcome 11: normal venous function (intermediate)
Thiswas reported byElsharawy 2002 andEnden2011 andpooling
of results showed a significant improvement with treatment (RR
2.98, 95% CI 1.75 to 5.08) (Analysis 4.12).
Outcome 12: recurrent venous thromboembolism (VTE)
(intermediate and late)
While DVT was not reported separately, intermediate recurrent
VTE was reported by Enden 2011 (RR 0.61; 95% CI 0.30 to
1.25; Analysis 4.13). At five year follow-up Enden 2011 reported
that 34 patients had recurrent thrombosis. Thirteen events were
in the ipsilateral leg, 10 in the contralateral leg, nine were PE
and two were unknown (RR 0.63, 95% CI 0.34 to 1.18; Analysis
4.14). Six patients with chronic iliac vein occlusions (one in the
CDT group and five in the control group), were referred and had
endovascular recanalsation with stenting. Although randomised
to the treatment group, the CDT patient had not received CDT
as planned due to technical failure (Haig 2016).
Outcome 13: quality of life
Enden 2011 was the only study to report on this outcome, us-
ing generic QoLmeasures (VEINES-QOL) and symptom specific
(VEINES-Sym) scales. After 24 months there were no differences
inQoLbetween the additionalCDTand standard treatment arms;
mean difference for the EQ-5D index was 0.04 (95% CI −0.10
to 0.17), for the VEINES-QOL score 0.2 (95% CI −2.8 to 3.0)
and for the VEINES-Sym score 0.5 (95% CI−2.4 to 3.4; P value
> 0.37). After 5 years Enden 2011 reported no difference in mean
generic QoL scores, disease specificQoL scores, or symptom sever-
ity score between the groups (see Enden 2012; Enden 2013a).
Independent of treatment arms, after 24months patientswith PTS
had poorer outcomes than patients without PTS; mean difference
for EQ-5D was 0.09 (95% CI 0.03 to 0.15), for VEINES-QOL
score 8.6 (95% CI 5.9 to 11.2) and for VEINES-Sym score 9.8
(95% CI 7.3 to 12.3; P value < 0.001). After five years the EQ-
5D, VEINES-QOL and VEINES-Sym scores for patients with
PTS were lower than for those without PTS (Enden 2012; Enden
2013a).
Outcome 14: cost comparisons
Cost comparisons were only reported by Enden 2011. Additional
CDTaccumulated 32.31quality-adjusted life years (QALYs) com-
pared with 31.68 QALYs after standard treatment. The lifetime
cost of CDT was USD 64,709 compared to USD 51,866 with
standard treatment. The incremental cost effectiveness ratio was
USD 20,429/QALY gained, and the study authors concluded that
the probability that CDT was cost effective was 82% at a will-
ingness to pay threshold of USD 50,000/QALY gained (Enden
2013b). CDT may have additional costs compared to systemic
administration.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Treatment with catheter directed thrombolysis for acute DVT
Patient or population: pat ients diagnosed with acute deep vein thrombosis
Setting: hospital
Intervention: catheter-directed thrombolysis
Comparison: control ant i-coagulat ion
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with control Risk with catheter di-
rected thrombolysis
Complete clot lysis (in-
termediate, 6 months
to under 5 years af ter
treatment)
Study populat ion RR 2.52
(0.52 to 12.17)
224
(2 RCTs)
⊕⊕⊕©
MODERATE 1
58 (of 116) pat ients treated with standard ant i-
coagulat ion had complete clot lysis compared to
81 (of 108) in the CDT group
Bleeding
(early, up to 1 month
af ter treatment)
Study populat ion RR 7.69
(0.40 to 146.90)
224
(2 RCTs)
⊕⊕⊕©
MODERATE 2
None (of 116) pat ients
in the standard ant i-
coagulat ion group had
bleeding complicat ions
compared to 3 (of 108)
in the CDT group
Cannot def ine risk as no events reported in the
standard ant icoagulat ion group
Post-thrombotic syn-
drome (intermediate, 6
months to under 5 years
af ter treatment)
Study populat ion RR 0.74
(0.55 to 1.00)
189
(1 RCT)
⊕⊕⊕©
MODERATE 3
55 (of 99) pat ients in
the standard ant icoagu-
lat ion group developed
PTS compared to 37 (of
90) in the CDT group
556 per 1000 411 per 1000 (306 to
556)
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Post-thrombotic syn-
drome
(late, 5 year follow-up
af ter treatment)
Study populat ion RR 0.60
(0.45 to 0.79)
176
(1 RCT)
⊕⊕⊕©
MODERATE 3
63 (of 89) pat ients in
the standard ant icoagu-
lat ion group developed
PTS compared to 37 (of
87) in the CDT group
708 per 1000 425 per 1000 (319 to
559)
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CDT: catheter-directed thrombolysis; CI: Conf idence interval; DVT: deep vein thrombosis; PTS: post-thrombotic syndrome; RCT: randomised controlled trial RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded by one level as conf idence intervals are wide around the est imate of the ef fect
2 Downgraded by one level as conf idence intervals wide around the est imate of ef fect. Studies did not report any bleeding
events in standard ant icoagulat ion group
3 Results are f rom one small study with a small number of events. Downgraded by one level
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D I S C U S S I O N
Summary of main results
The rationale for the use of thrombolysis for DVT is to prevent
long-term complications related to poor venus function including
PTS and ulceration. For this update it is encouraging that further
data on intermediate to longer-term outcomes are available to
assess these complications. Sixty-six per cent of control participants
at intermediate time points and sixty-seven per cent at late follow-
up experienced PTS, which is in line with other estimates. Pooling
all types of thrombolysis, the results showed a reduction in the
risk of PTS with use of thrombolysis by 34% at the intermediate
time point (RR 0.66; NNTB 5) and a reduction in the risk of
PTS of 42% at late follow-up (RR 0.58; NNTB 4). There was
no difference in ulceration beyond six months; data were limited
by small numbers and the short length of follow-up, as ulcers are
more likely to occur later than a year or two after the DVT.
CDT has been studied at the femoral and iliofemoral levels only,
where the risk of post-thrombotic complications is highest. Com-
parison four shows the results for the two recent trials which stud-
ied this method, which are comparable to the results for all routes
of thrombolysis combined.
There were not enough data in this review to make any definitive
comparison between the different agents or routes of administra-
tion for thrombolysis. Streptokinase appears to have been most
widely studied. Significant results were obtained by combining
studies including participants with DVT at a variety of levels of
the leg veins affected, while it is accepted that the likelihood of
later complications is less with clots at lower levels (Table 1).
The most marked effects with thrombolysis were seen in improve-
ment in vein patency and complete clot lysis measured by venog-
raphy, where both early and intermediate results showed impor-
tant differences between the control and treatment groups. The
use of objective classification of the degree of lysis would assist,
in the future, with quantifying this outcome and the patency of
the veins. There were not enough data to comment further on
venous function or recurrent DVT per se. Results relating to PE
were inconclusive due to uncertainty surrounding diagnosis.
The risk of inducing unwanted bleeding with thrombolytics has
been the most important factor limiting its use for patients with
DVT. Most bleeding episodes and deaths occurred in the earlier
studies. Bleeding episodes (excluding stroke) causing interruption
of therapy, interventions such as transfusion, or chronic sequelae (a
condition following as a consequence of a disease) occurred more
often with thrombolysis than with standard anticoagulation (RR
2.23; NNTH 17). There is no strong evidence that one particular
route of administration or agent was excessively hazardous in this
respect, although it is notable that no bleeding occurred in the
Elsharawy 2002 study. This may have been due to strict exclusion
criteria and the close radiological monitoring and dose titration
depending upon clot lysis. A high proportion of patients with
DVT are, however, unsuitable for thrombolytic treatment because
of extensive contra-indications.
Three intracerebral bleeds occurred in these trials (Common1976;
Goldhaber 1990; Marder 1977). Adoption of current contra-in-
dications may have prevented these events in more recent tri-
als. A stroke occurred in a participant with polycythaemia rubra
vera who received streptokinase (Common 1976), an intracranial
bleed in a participant with controlled hypertension treated with
tPA(Goldhaber 1990), and a fatal intracranial haemorrhage in a
patient with a remote history of cerebrovascular accident (Marder
1977). Two of the early deaths in the treatment groups may also
have been prevented with the use of current contra-indications to
thrombolysis: a participant with metastatic carcinoma (Common
1976), and a participant with recent surgery (Kakkar 1969).Other
deaths were incidental to the treatment or related to underlying
conditions.
The data on intermediate mortality were inconclusive. One trial
(Schweizer 2000) reported the absence of further PE episodes at
one year, however no other trials reported on this outcome. Other
adverse effects, for example allergic or anaphylactic reactions, were
not examined in this review.
No comparisons between thrombolysis and subcutaneous low
molecular weight heparin, administered at home, for DVT were
identified.
One study Enden 2011 examined both QoL and cost effective-
ness. For QoL there was no significant difference between CDT
and standard treatment although PTS was associated with a lower
QoL. The incremental cost effectiveness ratio was USD 20,429
per QALY gained (Enden 2013b). This incremental cost effec-
tiveness ratio for CDT is within the range for approval by bod-
ies making recommendation for implementation (Dakin 2014;
NICE PMG9).
Overall completeness and applicability of
evidence
The evidence presented is highly relevant to determining the ef-
fect of thrombolysis for DVT. The effectiveness of newer catheter-
directed methods appears to be similar to systemic administration.
Evidence suggests effectiveness at levels not limited to iliofemoral.
As there is a degree of consistency in the results of trials over time,
and in different settings, it is likely that the findings have external
validity. Further evidence is desirable to confirm the effect of newer
methods, and the factors predicting more successful outcomes. In
future a combination of invasive procedures to remove the clot,
with or without thrombolysis, may increase the proportion of pa-
tients who have effective clot removal; but that was out of the scope
of this review. With respect to standard treatment with anticoag-
ulation, selected patients may benefit from additional thrombol-
ysis directed by catheter, or systemic if this were considered safe.
This is in keeping with the current ’Recommendations and link
to evidence’ from NICE guidelines (NICE guidelines CG144).
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There are implications for inpatient treatment, where anticoagu-
lation for DVT is now delivered in outpatient settings, and for the
resourcing of more invasive procedures.
Quality of the evidence
This evidence is based on 17 trials involving 1103 participants
from a range of countries and settings. The key limitation of the
studies is the paucity of long-term follow-up data greater than one
year. The methodological quality of the studies was mostly high,
and the results were consistent across a range of settings and patient
groups. Using GRADE assessment, the body of evidence relating
to complete clot lysis (intermediate), bleeding (early) and PTS
(intermediate and late) was judged to be ofmoderate quality due to
many trials having low numbers of participants (See Summary of
findings for the main comparison; Summary of findings 2). There
were obvious differences between the inclusion criteria and the
conduct of studies completed over 40 years ago compared to more
recent studies. However, the results across studies were consistent
and we have reasonable confidence in the results.
Potential biases in the review process
It is likely that all relevant studies were identified and included.
Relevant data were requested or obtained from study authors, al-
though for older studies this was less likely to be successful. Efforts
were made to reduce bias in the review process by ensuring double
independent data extraction and quality assessment of studies.
Agreements and disagreements with other
studies or reviews
The evidence presented here is consistent with findings of other
reviews, which have included a broader range of evidence than
RCTs. A review of the literature by Patterson 2010 concluded that
in carefully selected patients CDT offered benefits in treatment,
although further trial evidence was needed. Vedantham 2010 indi-
cated benefits in CDT for people with extensive acute iliofemoral
DVT, low expected bleeding risk and good functional status, al-
though Comerota 2008 also emphasised a need for further re-
search. A meta-analysis by Du 2015 included both randomised
and non-randomised studies and had similar findings. Systemic
thrombolysis is not current practice although this review suggests
that it has similar effectiveness to CDT.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Thrombolysis offers potential advantages over standard treatment
for DVT, by reducing the proportion of patients with chronic
disabling leg symptoms from PTS by a third up to and beyond
five years from treatment. This finding is based on four trials with
a total of 341 participants, most of which have low risk of bias.
There was an increased risk of iatrogenic (resulting from medical
treatment or procedures) bleeding, but this risk has decreased over
time with the use of stricter exclusion criteria for thrombolysis.
Results from systemic thrombolysis and CDT appear similar. Ev-
idence suggests effectiveness for DVT above the level of the calf.
Patients with extensive thromboses, for example iliofemoral, may
have the most to gain in terms of preserving venous function, and
patient selection is important to reduce the risk of complications.
It was not possible to determine the optimum treatment regime in
terms of agent, dose and route of administration from this review.
Cost analysis from one study suggests that the incremental cost
effectiveness ratio for CDT is within the range for approval by
bodies making recommendation for implementation.
Implications for research
Future trials need to be large enough to detect significant clin-
ical outcomes and ideally last two to five years to estimate the
long-term effect of thrombolysis. CDT differs significantly, as a
technique, from systemic thrombolysis and further investigation
is needed using this method, particularly in the long term. It may
worth be re-visiting whether systemic thrombolysis can be used
safely in the modern era with careful patient selection. There are
also resource implications to introducing systemic or CDT in se-
lected patients due to the need for availability of skilled staff and in-
terventional resources. Access to such treatment where outpatient
management of DVT is undertaken may require service changes
and these factors will require appropriate consideration in health
economic studies which assess costs and cost effectiveness.
Use of thrombolysis in combination with interventional methods
of clot removal may offer benefit to a wider group of patients, and
the effect of temporary inferior vena cava filtration within this is
an area for study. Newer agents that cause less systemic bleeding
may hold promise for this condition.
It may be useful to differentiate the effects of PTS and thromboly-
sis on younger and older patients, the specific level of the clot, and
differing times from the initial event, for example 14 days or 21
days or sooner from symptom onset. The measurement and quan-
tification of lysis and the resulting patency of the vein is an area
for further study. Exclusions, such as malignancy, warrant further
study as these may become less significant in certain circumstances
with safer methods of treatment. One of the studies performed a
cost analysis and examined quality of life issues, but these too need
further research.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Arneson 1978
Methods Allocation: random
Single blind
Exclusions after randomisation: 1
Loss to follow-up: nil
Participants Country: Norway
Participants: 43
Age: < 70 years
Sex: Male and female
Inclusion criteria: inpatients with venographically confirmedDVT extending proximally
beyond the calf < 5 days duration
Exclusion criteria: bleeding dysfunction; surgery within 7 days; GI/GU bleeding; stroke;
diastolic BP > 120 mmHg; hypertensive retinopathy grade 3 - 4; renal/hepatic insuffi-
ciency; pregnancy; malignancy; age > 70
Interventions Treatment: streptokinase 250,000 U loading IV, then 100,000 IU/hour IV 72 - 96 hours
Control: heparin 15,000 IU IV bolus, 30,000 IU infusion IV 72 - 90 hours
Co-treatment: hydrocortisone 100 mg IV, then prednisolone 10 mg three times daily
during streptokinase infusion. Warfarin begun after streptokinase along with heparin
until warfarin effective
In control group, warfarin begun after 72 - 90 hours with continuation of heparin until
warfarin effective
Outcomes 21 days: mortality; PE; major bleeding; clot lysis
6 years: mortality; recurrent DVT; post-thrombotic syndrome; leg ulceration
Notes 40 randomised, 1 excluded as diagnosis of DVT in error
3 patients included who were not randomised, 2 streptokinase, 1 control
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “...performed by our statistician on the ba-
sis of random numbers”
Allocation concealment (selection bias) Low risk “ ...allocation to the treatment groups was
performed by using sealed envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk not possible due to intervention but judged
low risk as outcome assessment well de-
scribed
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Arneson 1978 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “the radiologic evaluation was done with-
out knowledge of the treatment given”
Incomplete outcome data (attrition bias)
All outcomes
Low risk no missing data
Selective reporting (reporting bias) Low risk all outcomes reported
Other bias Low risk none
Common 1976
Methods Allocation: random
Single blind
Exclusions after randomisation: nil
Losses to follow-up: 23 at 7 months
Participants Country: USA
Participants: 50
Age: > 18 years
Sex: Male and female
Inclusion criteria: venographically confirmed DVT duration < 14 days
Exclusion criteria: pregnancy; surgery or childbirth < 10 days; bleeding dysfunction;
peptic ulcer; recent streptococcal infection; active TB; carotid bruit; stroke < 6 months;
diastolic BP > 100mmHg; atrial fibrillation; hypertensive retinopathy grade 3/4; hepatic/
renal biopsy aortography < 14 days
Interventions Treatment: hydrocortisone 100mg IV then streptokinase IV 250,000Uover 30minutes,
then 100,000 U/hour titrated for 72 hours. Followed by IV heparin titrated over 7 days
Control: IV heparin 150 U/kg loading dose then titrated for 10 days
Co-treatment: warfarin given from day 6 - 7
Outcomes 3 - 10 days: clot lysis; bleeding; stroke; mortality
7 months: clot lysis
Notes Did not specify whether arm vein thrombosis included or not
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk stated “randomized” but no further details
given
Allocation concealment (selection bias) Unclear risk not described
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Common 1976 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk not described but judged as low risk of bias
as outcome assessment blinding described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “..two radiologists who were unaware of
the patient’s treatment were evaluated the
venograms...”
Incomplete outcome data (attrition bias)
All outcomes
Low risk no missing data
Selective reporting (reporting bias) Low risk all outcomes reported
Other bias Low risk none
Elliot 1979
Methods A prospective, controlled, randomised, comparative study to compare conventional full
dose heparin and streptokinase (Kabikinase)
Participants Country: South Africa
Total randomised: 51 (strep 26, hep 25)
Sex: Male (17) and female (34)
Mean age hep group: 51 years; strep group: 48 years
Inclusion criteria: proximal vein thrombosis diagnosed by bilateral ascending phlebo-
graph and less than 8 days clinical history of DVT
Exclusion criteria: any surgery within 7 days or neurosurgical within 2 months, preg-
nancy, menstruation, haemorrhagic diatheses, diastolic blood pressure of 110 mmHg,
suspected or know bleeding lesions, cerebrovascular accident within 6 months, recent
streptococcal infection, previous streptokinase therapy within 6 months, liver or renal
disease
2 patients in strep group had axillary vein thrombosis
Interventions Treatment: 100 mg of hydrocortisone 15 mins prior to first streptokinase dose and
repeated 6 hourly for duration of strep treatment. Strepokinase (Kabikinase) loading
dose of 600,000 U given by infusion over a period of 30 mins. Then 100,000 U hourly
for 3 days by infusion pump. Then heparin for 4 days dose adjusted to maintain Lee-
White clotting time to at least 2.5 - 3 normal
Control: At diagnosis 10,000 U of heparin given by iv injection. The 10,000 U iv 6
hourly using constant infusion pump. Dose adjusted to maintain Lee-White clotting
time to at least 2.5 - 3 normal
Treatment continued for 7 days
30 mg warfarin given as a loading dose to both groups 36 hours before heparin therapy
terminated, warfarin continued for 8 weeks, dose adjusted to maintain pro-thrombin
index 40 - 60 per cent
All participants bed rest for duration, foot of bed raised by 60 cm, elastic support provided
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Elliot 1979 (Continued)
Outcomes Mortality, complete lysis, bleeding, PE, valve function, PTS symptoms 6-33 months
(mean 19 months)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk no details given
Allocation concealment (selection bias) Unclear risk no details given
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk no details given but judged low risk as out-
come assessment well described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “..all radiographs were assessed on a blind
basis”
Incomplete outcome data (attrition bias)
All outcomes
Low risk no missing data
Selective reporting (reporting bias) Low risk all outcomes reported
Other bias Low risk none
Elsharawy 2002
Methods Allocation: random
Single blind
Exclusions after randomisation - nil
Losses to follow-up - nil
Participants Country: Egypt
Participants: 35
Age: < 70 years
Sex: Male and female
Inclusion criteria: iliofemoral venous thrombosis confirmed by duplex or venography
duration < 10 days; life expectancy > 6 months
Exclusion criteria: surgery < 14 days; previous CVA/CNS disease; GI bleed < 1 year;
BP > 180/100; pregnancy etc.; other contraindications to thrombolysis not explicitly
described
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Elsharawy 2002 (Continued)
Interventions Treatment: catheter-directed thrombolysis with streptokinase using popliteal approach.
Pulse spray given then vein assessed using contrast every 15 minutes. In 1 hour 1 mil-
lion U given. Followed by low dose infusion 100,000 U/hour, assessed every 12 hours.
Stoppedwhen complete lysis achieved, no progress in 12 hours or complication occurred.
Followed by anticoagulation
Control: heparin IV bolus 5000 U, then adjusted continuous infusion. Warfarin begun
the same evening
Co treatment: none described
Outcomes 1 week: clot lysis; bleeding; mortality; PE
6 months: clot lysis; venous function
Notes Catheter-directed thrombolysis, as distinct from systemic or loco-regional
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “...computer designated cards assigning pa-
tients to either groups”
Allocation concealment (selection bias) Unclear risk not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk not possible due to intervention but judged
low risk as outcome assessment well de-
scribed
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “ ..panel unaware of the sequencing of the
studies or if images were obtained at base-
line, 24 - 48 hours after randomisation or
before discharge”
Incomplete outcome data (attrition bias)
All outcomes
Low risk complete data available
Selective reporting (reporting bias) Low risk pre-specified outcomes reported
Other bias Low risk none
Enden 2011
Methods Multicentre, open label, randomised controlled trial of the efficacy and safety of addi-
tional catheter-directed thrombolysis (CDT) with alteplase
Three years duration (January 2006 to January 2009)
Ethical approval obtained
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Participants Country: Recruited from 20 centres, 8 hospital trusts in Norway
Total randomised: 189
Age: 18 to 75 years
Sex: Male and female
Inclusion criteria: objectively verified (diagnostic imaging) first time DVT in the upper
thigh, common iliac vein, or combined iliofemoral segment, symptom duration up to
21 days
Exclusion criteria: Anticoagulant treatment before trial entry (> 7 days previous), con-
traindications to thrombolytic treatment, indications for thrombolytic treatment, se-
vere anaemia, thrombocytopenia, severe renal failure, sever hypertension, pregnancy or
thrombosis within 7 days postpartum, less than 14 days postsurgery or post-trauma,
history of subarachnoid or intracerebral bleeding, disease with life expectancy less than
24 months, drug misuse or mental disease that could interfere with treatment and fol-
low-up, former ipsilateral proximal DVT, malignant disease needing chemotherapy, any
thrombolytic treatment within 7 days before trial inclusion
Interventions Treatment with CDT (number randomised 90)
Anticoagulation with subcutaneous LMWH (dalteparin or enoxaparin) for at least 5
days, discontinued for at least 8 hours before CDTreintroduced with warfarin 1 hour
after procedure. Infusion catheter covering thrombosed segments introduced under ul-
trasound. 20 mg alteplase diluted 500 mL 0.9% NaCl given at 0.01 mg/kg per hr for a
maximum 96 hrs. Maximum dose 20 mg/24 hrs. Unfractionated heparin given simul-
taneously as a continuous iv infusion, dose adjusted to keep activated partial throm-
boplastin time at 1.2 to 1.7 times higher than the upper normal limit. No additional
antiplatelet treatment given. Use of adjunctive angioplasty and stents to establish flow
and obtain less than 50% residual stenosis left to the discretion of the operator. Advised
to wear knee high elastic compression stockings (class II) daily for 24 months
Control (number randomised 99)
Anticoagulation with subcutaneous LMWH (dalteparin or enoxaparin) and warfarin for
at least 5 days, followed by warfarin alone to target intensity INR 2 to 3. Advised to wear
knee high elastic compression stockings (class II) daily for 24 months
Outcomes PTS at 6 and 24 months, and 5 years measured using Villalta score and classified as PTS
if score 5 or over, or if venous ulcer present
Iliofemoral patency, graded daily during thrombolysis, 6 months and 24 months and 5
years
Bleeding complications defined as major if clinically overt, or haemoglobin decrease of
2 g per decilitre or more, transfusion of 2 or more units of red cells or whole blood,
retroperitoneal or intracranial, occurred in a critical organ or contributed to death
Clinically relevant/non-major bleeding: epistaxis requiring intervention, large visible
haematoma on skin, spontaneous macroscopic haematuria
Venous function: at 6 months and 24 months, doppler ultrasound using pneumatic cuff
with patient standing, standardised compression unit, venous incompetence with reflux
valve closure time > 0.5 seconds
Functionally significant venous obstruction was indicated by a decline in the plethysmo-
graphic curve measured by APG (Macrola, Norway). Iliofemoral patency was defined
as regained when flow in the pelvic and femoral vein and complete compressibility of
the femoral vein was assessed by ultrasound; and no functional venous obstruction was
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Enden 2011 (Continued)
indicated by APG
Recurrent VTE; verified with routine imaging at local trial site
Mortality at 24 months and 5 years
Health related quality of life: EQ-5D measuring mobility, self care, activity, pain and
anxiety at 6 month, 24 months and 5 years
VEINES QoL/Sym specific to lower limb problems, measures symptoms, limitation,
psychological impact over 4 weeks and change over a year, carried out at 6 months, 24
months and 5 years. VEINES-QOL assesses QoL and VEINES-Symmeasures symptom
severity only
Cost effectiveness: Markov model, examining PTS, bleeding from CDT and post DVT
states, costs in US$, third party payer and lifetime horizon. One way and probabilistic
sensitivity analysis in hypothetical cohort age 50. Discounted costs and utilities 3%
annually. Long term cumulative incidence after 8 years 30% PTS, 88% severe PTS.
QALY, costs, incremental cost-effectiveness ratio
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “...multi-centre, open label, randomised
controlled trial..”. Random sequence gen-
erated with the website www.randomiza-
tion.com
Allocation concealment (selection bias) Low risk “...sealed opaque, numbered envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk blinding of participants not possible due to
the nature of the interventions, judged not
to effect outcome as these very well defined
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk assessors had “no knowledge of patient his-
tory or treatment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk well described. “Missing outcome data be-
cause of withdrawal of consent or death
from cancer or other causes not related to
CDT or anticoagulation were assumed to
be missing independently of treatment and
not included in the analyses”
Selective reporting (reporting bias) Low risk all outcomes reported
Other bias Low risk other bias unlikely although we note that
compliance with compression stockings is
slightly higher in intervention group: 63%
versus 52%
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Goldhaber 1990
Methods Allocation: random
Single blind
Exclusions after randomisation: nil
Losses to follow-up: nil
Participants Country: USA
Participants: 64 patients, 65 randomisations
Age: 18 to 75 years
Sex: Male and female
Inclusion criteria: venographically documented DVT, in popliteal or more proximal
veins < 14 days duration
Exclusion criteria:major bleeding; bleedingdysfunction; stroke; head trauma<3months;
GI/GUbleed <4weeks; trauma/surgery <14days; renal/hepatic dysfunction; therapeutic
warfarin; lactation/pregnancy; low platelet count; contraindication to contrast agent
Interventions Treatment (2 groups):
tPA alone 0.05 mg/kg/hour IV over 24 hours, then heparin 100U/kg bolus, then 1000
U/hour, adjusted
tPA as above plus heparin concomitantly as above
Control: heparin alone 100 U/kg bolus, then 1000 U/hour
Co-treatment: warfarin begun in all groups on second day
Heparin adjusted in all groups
Outcomes 36 hours: clot lysis; bleeding
Notes 2 patients were not treated according to randomisation, one receiving tPA, one receiving
heparin
5 of 65 venograms not analysed. 1 patient with recurrent DVT was re-entered - 64
patients 65 randomisations
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “randomly assigned to (groups) by opening
the appropriate consecutively numbered
sealed envelope according to a 2:2:1 allo-
cation scheme. Seperate treatment assign-
ments were generated block random num-
ber sequences”
Allocation concealment (selection bias) Unclear risk open label trial
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “both patients and investigators knew
which drug regimenwas being utilized” but
judged low risk as outcome assessment well
described
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Goldhaber 1990 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “images compared and assessed by a vas-
cular imaging panel that was blinded to
randomization assignment and unaware of
whether images were obtained at baseline,
24 to 48 hours after randomization or be-
fore discharge”
Incomplete outcome data (attrition bias)
All outcomes
Low risk all accounted for
Selective reporting (reporting bias) Low risk all outcomes reported
Other bias Low risk none
Goldhaber 1996
Methods Randomised controlled trial to assess efficacy and safety of rUK compared to heparin
alone
September 1992 to April 1994
361 screened, total randomised: 17
Allocation on 1:1 basis on morning of treatment
Open labelled study
Written informed consent
Participants Country: USA
Participants: 17
Symptoms of DVT < 14 days
Age: > 18 years
Sex: Male and female
Inclusion criteria: DVT diagnosed by ultrasonography or venography for proximal lower
extremity (popliteal,femoral, iliac veins with or without calf vein thrombosis) or MRI
for upper extremity (brachial, axillary, subclavian, internal jugular veins)
Exclusion criteria: stroke, intracranial disease or trauma, major chronic bleeding, major
GI bleedingwithin one year,major urological bleeding 1month, trauma ormajor surgery
at non-compressible site within 14 days, hypertension > 180/110 mm Hg, haematocrit
< 25% or platelet count < 100,000/mm3 , pregnancy, nursing mothers, occult blood in
stool, gross haematuria
Interventions Recombinant urokinase group: 3 bolus infusions of 250,000 U in 5 mins via peripheral
vein followed by continuous infusion of 750,000 U over 25mins and 8 hours after initial
dose. Final dose 24 hours after initial dose. Heparin administered 12 hours after first
rUK dose for 12 hours until final rUK dose. Three hours after final rUK hep resumed
to maintain activated PPT time of 60 to 80 seconds. Warfarin started the same evening
to maintain INR of 2 to 3
Heparin group: initial bolus of 5000 to 10,000 U if they were not already receiving
IV hep, then continuous infusion adjusted to maintain activated PPT time of 60 to 80
seconds. First dose of warfarin given within 24 hours of randomisation, target INR was
2 to 3
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Goldhaber 1996 (Continued)
Outcomes Clot lysis, venous flow, blood count and bleeding complications, fibrinogen levels
Notes 1 patient in each group had upper extremity DVT
UK group had longer duration of symptoms (6 days versus 3 days)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk randomisation method not described
Allocation concealment (selection bias) Unclear risk open label
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk no details given but judged low risk as out-
come assessment well described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “...images compared and assessed by vascu-
lar panel blinded to randomisation assign-
ment and time point of image”
Incomplete outcome data (attrition bias)
All outcomes
Low risk all data reported
Selective reporting (reporting bias) Low risk all outcomes reported
Other bias Low risk none
Kakkar 1969
Methods Allocation: random
Single blind
Exclusions after randomisation: 2
Losses to follow-up: nil
Participants Country: UK
Participants: 30
Age: 18 to 77 years
Sex: Male and female
Inclusion criteria: venographically confirmed DVT of leg duration < 4 days
Exclusion criteria: surgery < 3 days; unhealed wound; peptic ulcer; diastolic BP > 100
mmHg
Interventions Treatment: (2 groups) streptokinase 500,000 U IV over 30 minutes, 900,000 U every 6
hours for 5 days or (Arwin) 80 U in 6 hours, then 80 units in 15 minutes, then 40 - 80
U every 6 hours for 5 days
Control: heparin 10,000 U over 5 minutes, then 10,000 to 15,000 U every 6 hours for
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Kakkar 1969 (Continued)
5 days
Co-treatment: oral anticoagulation commenced at end of infusions. Bed rest, leg eleva-
tion, bandages to all groups
Outcomes 1 month: mortality; PE; clot lysis; bleeding
6 to 12 months: clot lysis after partial lysis
Notes 1 excluded as died of PE in heparin group. 1 excluded due to bleeding in streptokinase
group
Included 7 patients with tibial vein thrombosis only (4 heparin, 2 streptokinase, 1 Arwin)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk description not clear
Allocation concealment (selection bias) Unclear risk description not clear
Blinding of participants and personnel
(performance bias)
All outcomes
High risk not described
Blinding of outcome assessment (detection
bias)
All outcomes
High risk not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk no missing data
Selective reporting (reporting bias) Low risk all outcomes reported
Other bias Low risk none
Kiil 1981
Methods Allocation: random
Double blind
Exclusions after randomisation: 1
Losses to follow-up: nil
Participants Country: Denmark
Participants: 20
Age: 17 to 79 years
Sex: Male and female
Inclusion criteria: venographically confirmed DVT duration < 72 hours
Exclusion criteria: not described
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Interventions Treatment: urokinase 200,000 U IV over 24 hours. After 18 hours, heparin loading dose
of 15,000 units then 40,000 U/day for 5 days
Control: heparin 40,000 U/day IV for 6 days
Co-treatment: not described
Outcomes 6 days: clot lysis; bleeding
2 weeks: mortality
Notes 1 excluded from heparin group due to bleeding. Low dose urokinase. Did not specify
whether calf vein thrombosis was included
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly separated” but no further details
given
Allocation concealment (selection bias) Unclear risk “allocation of the patients ... was performed
by one of the participants” no further de-
tails given
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “mixture of liquids to be infused was per-
formed by one of the participants”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “clinical evaluation and interpretation of
phlebograms were preformed in a double-
blind fashion”
Incomplete outcome data (attrition bias)
All outcomes
Low risk exclusions explained
Selective reporting (reporting bias) Low risk all outcomes reported
Other bias Low risk none
Marder 1977
Methods Randomised controlled trial, single blind, “..to provide evidence that lytic agents are
more effective than heparin in dissolving venous thrombi”
Declaration of Helsinki, written and verbal explanation of procedures and risks of study,
written and informed consent
Participants Country: USA
Participants: 24 randomised; 12 heparin and 12 strep (plus 3 non-randomised)
Age over 18 years mean age in hep 50.2 and strep 54.7 years
Male and females with venographically proved peripheral DVT
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Marder 1977 (Continued)
Mean symptom duration in heparin group was 6.2 days and 8.5 days for the strep group
Patients were included in study if ’no evidence of hemorrhagic tendency, active gastroin-
testinal or genitourinary bleeding, severe system hypertension, atrial fibrillation, preg-
nancy, 10 days post partum, surgery, hepatic or renal biopsy, translumbar aortography.
Four patients in strep group had tumours, three had obstructed venous return in veins
which contained thrombus. Two patients (one each heparin and strep), had thrombosis
of upper extremity
Interventions All patients iv bolus injection of 100 mg hydrocortisone prior to start of strep or hep
Treatment: strepwas administered as a priming dose of 250,000U in 20minute, followed
by a maintenance infusion of 100,000 U/hour for 72 hours
Control: heparin was administered as an initial iv dose of 150 U/kg of body weight over
5 minutes followed by a 72 hour infusion at a rate which prolonged the PTT to 60 to
100 seconds
After 72 hours of treatment both groups received continuous or intermittent iv heparin
according to guidelines. A maintenance dose of warfarin (coumadin) was administered
on day seven and heparin was discontinued when the prothrombin time was prolonged
to 1.5 to 2.5 times the control value. Warfarin was continued for three months or longer
at physicians discretion
Outcomes Venography (pre-treatment and five days post treatment), haemostasis, complications
Notes Three patients were added in a non-randomised fashion to the streptokinase group.
Mean age 56 years and symptom duration 8.7 days. These patients were added as three
patients from the randomised group did not have follow-up venograms
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “..after entry patients were randomly allo-
cated to either the heparin or the streptok-
inase group...” but it is not clear by which
method this was done
Allocation concealment (selection bias) Unclear risk no information given
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk no attempt to blind described but this
judged low risk to be consistent with risk
of bias assessing of other studies
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk for assessment of venography “films were
interpreted independently (by two authors)
...without knowing the drug administered
or whether the study was before or after
treatment”. For bleedingno clear definition
for grading or assessment are given
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Marder 1977 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk although possible to separate the non-ran-
domised data for venography, it is not pos-
sible to do so for bleeding outcomes
Selective reporting (reporting bias) High risk not possible to determine which results
from randomised patients for all outcomes
Other bias High risk three non-randomised patients added to
study post-randomisation
Schulman 1986
Methods Allocation: random
Single blind
Exclusions after randomisation: 2
Losses to follow-up: nil
Participants Country: Sweden
Participants: 38
Age: 26 to 74 years
Sex: Male and female
Inclusion criteria: venographically confirmed calf vein thrombosis
duration < 7 days
Exclusion criteria: previous thrombosis same leg; contraindication to thrombolysis
Interventions Treatment: streptokinase 50,000 IU IV over 15 minutes then 100,000 IU over 12 hours
for up to 7 days, titrated. Given with 5000 IU heparin IV over 12 hours. Warfarin begun
after streptokinase ended
Control: heparin 5000 IU IV bolus then 30,000 IU per day, titrated for 7 days. Warfarin
begun simultaneously
Co-treatment: paracetamol, hydrocortisone or moduretic if necessary. 24 hours bed rest.
Warfarin given for 5 to 6months. Leg elevation. Elastic bandages. Elastic stockings where
swelling or venous insufficiency detected at discharge or follow-up
Outcomes 1 week: bleeding; clot lysis (venographic score); mortality; stroke; PE
1 month: clot lysis
1 year: clot lysis
Up to 5 years: post-thrombotic syndrome; foot volumetry
Notes Low dose streptokinase. 2 patients excluded after randomisation, as they had previous
thromboses
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk “randomised, prospective study” but no
further details given
Allocation concealment (selection bias) Low risk “allocated using sealed envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk not possible due to the nature of the in-
terventions but judged low risk as outcome
assessment well described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “..venograms were evaluated blindly in ret-
rospect by one and the same radiologist”
Incomplete outcome data (attrition bias)
All outcomes
Low risk no missing data
Selective reporting (reporting bias) Low risk all outcomes reported
Other bias Low risk none
Schweizer 1998
Methods Allocation: random
Single blind
Exclusions after randomisation: 2
Losses to follow-up: 1
Participants Country: Germany
Participants: 69
Age: 22 to 58 years
Sex: Male and female
Inclusion criteria: venographically confirmed DVT of leg duration < 7 days
Exclusion criteria: PE; calf vein thrombosis; recurrentDVT; GI/GUbleed; inflammatory
bowel disease; acute pancreatitis; surgery within 4 weeks; IM injection within 10 days;
hypertensive retinopathy grade 3 or 4; intracerebral disease; cerebral surgery or trauma
within 3 months; malignancy not in remission; diabetic retinopathy stage 3 or 4; renal
or hepatic failure; bleeding dysfunction; pregnancy, lactation, delivery within 20 days
Interventions Treatment: (2 groups) tPA 20 mg IV into pedal vein over 4 hours each day for 7 days.
Heparin IV given concomitantly, with adjustment
Urokinase 100,000 IU/hr IV into pedal vein continuously for 7 days. Heparin IV for 7
days. Plasminogen monitored Warfarin from day 7 to 12 months
Control: heparin IV, adjusted for 7 days
Co-treatment: bed rest and compression treatment. Warfarin from day 7- 12 months
in treatment groups. Warfarin begun immediately, for 12 months in control group.
Compression for 12 months for all patients
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Schweizer 1998 (Continued)
Outcomes 7 days: bleeding; clot lysis (no results for control group)
1 year: post-thrombotic syndrome
Notes Loco-regional thrombolysis. 2 patients excluded due to bleeding, 1 tPA, 1 urokinase. 1
lost to follow-up from control group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “...designed by a biometrician who was not
involved in the study”
Allocation concealment (selection bias) Unclear risk no details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk not described but judged unlikely to influ-
ence outcome assessment as well described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “...evaluated by an independent radiologist
who was unaware of the treatment the pa-
tients had received”
Incomplete outcome data (attrition bias)
All outcomes
Low risk no missing data
Selective reporting (reporting bias) Low risk all outcomes reported
Other bias Low risk none
Schweizer 2000
Methods Allocation: random
Single blind
Exclusions after randomisation: nil
Losses to follow-up: 12
Participants Country: Germany
Participants: 250
Age: mean 40 years
Sex: Male and female
Inclusion criteria: thrombosis of popliteal ormore proximal veins confirmedby venogram
at more than one level duration < 9 days
Exclusion criteria: no PE; recurrent DVT; calf vein thrombosis only; GI/GU bleeding;
inflammatory bowel disease < 12 months; acute pancreatitis; surgery or head trauma
< 3 months; IM injection < 10 days; hypertension; diabetic retinopathy stage 3 - 4;
malignancy; renal or hepatic failure; bleeding dysfunction; pregnancy, lactation, delivery
within 20 days
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Interventions Treatment: (4 groups) local tPA 20 mg/day, over 4 hours via pedal vein for 4 to 7 days.
IV heparin given simultaneously at 1000 IU/hour, adjusted
Local urokinase 100,000 IU/day infused continuously. Fibrinogen and plasminogen
monitored. Heparin IV given concomitantly
Systemic streptokinase 3,000,000 U/day over 6 hours in conjunction with heparin for
up to 7 days. Premedication: hydrocortisone 100 mg, ranitidine 50 mg, clemastine 2 mg
Systemic urokinase 5,000,000 IU/day over 4 hours for up to 7 days. IV heparin given
concomitantly
Control: heparin IV, adjusted
Co-treatment: bedrest, compression bandages, warfarin and compression treatment con-
tinued for 12 months
Outcomes 7 days: PE; major bleeding; mortality; clot lysis
1 year: clot lysis
Notes 4 losses to follow-up in systemic urokinase, systemic streptokinase and control groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “patients were randomly assigned” no fur-
ther details given
Allocation concealment (selection bias) Unclear risk no details given
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk not described but judged low as outcome
assessment well described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “..one dedicated radiologist, blinded to
the patient’ treatment regimens, evaluated
the venograms, while another assessed the
sonographic data”
Incomplete outcome data (attrition bias)
All outcomes
Low risk no missing data
Selective reporting (reporting bias) Low risk all outcomes reported
Other bias Low risk none
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Tsapogas 1973
Methods Allocation: random
Not blind
Exclusions after randomisation: nil
Losses to follow-up: nil
Participants Country: USA
Participants: 34
Age: mean 57 years
Sex: Male and female
Inclusion criteria: DVT confirmed by venogram
duration < 5 days
Exclusion criteria: diastolic BP > 120 mmHg; peptic ulceration; bleeding dysfunction;
allergic condition; surgery < 7 days; recent streptococcal infection; streptokinase given <
6 months
Interventions Treatment: titrated dose of streptokinase IV into ankle vein 100 mg hydrocortisone
IV prior to therapy and daily for 5 days. Streptokinase 100,000 U/hr maintained and
adjusted up to 72 hours. IV heparin for 1 week 6 to 12 hours after streptokinase
Control: heparin IV into affected limb, 7000 U bolus then 1500 U/hr adjusted. Con-
tinued for 7 days after 48 hours of treatment
Co-treatment: bed rest, elevation of leg.Warfarin 2 days before end of therapy, continued
for 4 weeks
Outcomes 7 days: clot lysis
Notes Loco-regional administration of streptokinase and heparin
Calf vein thrombosis included, number not specified, equal in both groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “based on a list of random numbers”
Allocation concealment (selection bias) Unclear risk “arranged by using sealed envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk not described
Blinding of outcome assessment (detection
bias)
All outcomes
High risk not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk no missing data
Selective reporting (reporting bias) Low risk all outcomes reported
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Other bias Low risk none
Turpie 1990
Methods Allocation: random
Double blind
Exclusions after randomisation: nil
Losses to follow-up: 37
Participants Country: Canada
Participants: 83
Age: < 75 years
Sex: not described
Inclusion criteria: venographically confirmed proximal DVT of lower limb
duration < 7 days
Exclusion criteria: bleeding dysfunction; active bleeding; peptic ulcer; stroke or intracra-
nial process < 2 months; surgery, trauma, childbirth, biopsy, vessel puncture < 7 days
Interventions Treatment: IV heparin 5000 U bolus then 30,000 U/24 hours, adjusted for 7 - 10 days
Phase 1: two chain tPA 0.5 mg/kg IV over 4 hours
Phase 2: one chain tPA 0.5 mg/kg IV over 8 hours and repeated in 24 hours
Control: identical placebo to tPA depending on phase, plus heparin as above
Co-treatment: warfarin commenced for 3 months
Outcomes 24 - 48 hours: clot lysis; bleeding
3 years: post-thrombotic syndrome
Notes 22 died, 15 “not available” for intermediate to late follow-up
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly allocated” no further details
Allocation concealment (selection bias) Unclear risk not described clearly
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “identical appearing placebo”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “venograms interpreted by an independent
panel without knowledge of the clinical
findings or the treatment group”
Incomplete outcome data (attrition bias)
All outcomes
Low risk all reported
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Selective reporting (reporting bias) Low risk all reported
Other bias Low risk none
Ugurlu 2002
Methods Prospective study to compare efficacy and safety of low dose, slow infusion thrombolysis
Randomised
Participants Country: Turkey
Age: 18 to 70 years
Number: 97, 50 low dose strep, 47 hep
June 1995 to May 1999
Sex: Male and female
Informed consent
Baseline characteristics similar
Inclusion criteria: DVT confirmed with high resolution colour duplex
Exclusion criteria: history of stroke, intracranial haemorrhage, major GI, urological ir
genital haemorrhage, major trauma or surgery within 20 days, hypertension, known
bleeding diathesis, post partum, nursing or pregnant women
Interventions Strepokinase group: Methylprednisone 250 mg IV with IV antihistaminic prior to 250,
000 U given in 30 mins via forearm vein, then infusion of 100,000 U/hour. Infusion
stoppedwhen adose of 1,500,000U.Thenheparin according to prothrombin andpartial
thromboplastin times and duplex study done. Urokinase administered in 2 patients who
had severe allergic reaction to strep - bolus of 100,000 U then infusion of 100,000 U
per hour for a total dose of either 1,500,000 or 3,000,000 U
Heparin group: bolus of 5000 U, then infusion of 1-1500 U/hr.Dose adjusted according
to the activated partial thromboplastin time
Both groups: bed rest and elevation, coumadin started 48 hours later according to pro-
thrombin times, INR of 2 - 3
Outcomes Venous flow, clinical assessment, haemorrhagic complications, allergic reaction
Notes Recurrent DVT included (30% each group)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “randomised number table”
Allocation concealment (selection bias) Unclear risk not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk not possible but judged low risk as outcome
assessment well described
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Ugurlu 2002 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “...initial and post-treatment duplex stud-
ies preformed by same radiologist unaware
of groups..”
Incomplete outcome data (attrition bias)
All outcomes
Low risk all accounted for
Selective reporting (reporting bias) Low risk all outcomes reported
Other bias Low risk none
Verhaeghe 1989
Methods Allocation: random
Double blind
Exclusions after randomisation: nil
Losses to follow-up: nil
Participants Country: France, Belgium, Switzerland
Participants: 21 (in randomised phase only)
Age: 22 to 74 years
Sex: Male and female
Inclusion criteria: hospitalised patients with DVT of popliteal or more proximal veins
of the lower leg, confirmed by venography
duration < 10 days
Exclusion criteria: pregnancy; major surgery < 72 hours; stroke < 6 months; head trauma
< 1 month; diastolic BP > 120 mmHg; renal/hepatic disease; peptic ulcer; bleeding
dysfunction; contraindication to heparin
Interventions Treatment: (2 groups)
IV tPA 100 mg on day 1, 50 mg tPA on day 2. 10% of dose given as bolus
IV tPA 50 mg on day 1, repeated on day 2. 10% of dose given as bolus
Control:
identical placebo infusion as above
Co-treatment: heparin 5000 U IV bolus then continuous infusion of 1000 U per hour
for up to 72 hours
Outcomes 72 hours: clot lysis; bleeding
Notes Included initial open label phase in some results (11 additional patients)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly allotted” not described further
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Verhaeghe 1989 (Continued)
Allocation concealment (selection bias) Unclear risk not clearly described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Two radiologists interpreted all filmswith-
out knowing the drug administered or
whether the venography was before or after
trial treatment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “no protocol violations”
Selective reporting (reporting bias) Low risk all outcomes reported
Other bias Low risk none
BP: blood pressure
CDT: catheter-directed thrombolysis
CNS: central nervous system
CVA: cerebrovascular accident
DVT: deep vein thrombosis
GI: gastrointestinal
GU: genitourinary
hep: heparin
Hg: mercury
IM: intramuscular
IU: international unit
PE: pulmonary embolism
strep: streptokinase
TB: tuberculosis
tPA: tissue plasminogen activator
U: unit
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ansell 1990 Insufficient information despite contacting author
Bashir 2014 Not randomised
Bieger 1976 DVT not confirmed objectively
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(Continued)
Browse 1968 Not randomised
Cakir 2014 Thrombectomy not thrombolysis
Engelberger 2015 Not CDT versus anticoagulant
Johansson 1979 Not truly randomised
Marini 1991 Both groups received thrombolysis
Markevicius 2004 Not truly randomised
Patra 2014 Included patients with DVT 0 - 8 weeks, not clear if randomised, CDT in addition to thrombectomy
Persson 1977 Insufficient information, unable to contact author
Pinto 1997 No thrombolytic
Robertson 1967 Not truly randomised
Santiago 2014 Prospective observational clinical study in children only
Sas 1985 Insufficient information, unable to contact author
Schweizer 1996 Control group not randomised
Silistreli 2004 Included patients with symptoms for more than 21 days
Sui 2013 Compares thrombolytics, not CDT versus anticoagulant
Tibbutt 1974 Ancrod used as control
Tibbutt 1977 All patients received streptokinase
TORPEDO 2012 Only 33 out of 90 patients received thrombolysis
Zhang 2014 CDT verses CDT plus angioplasty
Zimmermann 1986 Both groups received thrombolysis
DVT: deep vein thrombosis
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Characteristics of ongoing studies [ordered by study ID]
IRCT201108035625N3
Trial name or title Traditional medical treatment versus interventional approach in acute iliofemoral vein thrombosis
Methods Single centre randomised controlled clinical trial comparing the effect of conventional therapy (heparin
followed by warfarin) with interventional therapy (thrombolysis with or without angioplasty and stenting)
on venous patency in patients admitted with acute iliofemoral DVT to Tehran Heart Center emergency
department
Participants Patients with acute extensive iliofemoral venous thrombosis
Interventions Intervention: lytic therapy will be achieved by placing a catheter in the contralateral femoral vein, the right
internal jugular vein, or the ipsilateral popliteal vein for direct intra-clot infusion. Streptokinase will be given
as a loading dose of 250,000 units followed by infusion of 100,000 units per hour for 24 to 48 hours. Heparin
will be administered concomitantly with the lytic therapy and continued until therapeutic anticoagulation
with warfarin will be accomplished. After lytic therapy, further intervention (PTA/stenting) will be performed
if there is an underlying venous stenosis of 50% or more. Stent placement will be done with appropriate
selected stents (self-expanding stainless steel wall stents). All stented patients will be given warfarin indefinitely
(INR 2 - 3). Lysis will be considered complete if there is less than 5% residual thrombus
Control: conventional treatment will consist of intravenous heparin followed by warfarin. All patients will
be treated with limb elevation and moist heat during their initial admission and maintained on prescription
gradient compression stockings
Outcomes Venous patency and symptom changes
Starting date August 2011
Contact information Dr Yaser Jenab Tehran Heart Center jenab@razi.tums.ac.ir
Notes http://www.irct.ir/searchresult.php?keyword=&id=5625&number=3&prt=2274&total=10&m=1 (accessed
29/02/2016)
NCT00790335
Trial name or title Acute Venous Thrombosis: Thrombus removal with adjunctive catheter-directed thrombolysis (ATTRACT)
Methods Optimal standard DVT therapy to standard plus CDT
Participants Age 16 to 75 years old with symptomatic proximal DVT involving iliac, common femoral and or femoral
vein
Interventions Recombinant tissue plasminogen activator (rt-PA)
Outcomes Incidence of post-thrombotic syndrome 24 months after intervention; major bleeding
Starting date November 2009
Contact information Patty M Nieters nietersp@mir.wustl.edu
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NCT00790335 (Continued)
Notes NCT00790335
NCT00970619
Trial name or title DUTCH CAVA-trial: CAtheter Versus Anticoagulation Alone for Acute Primary (Ilio)Femoral DVT.
(NL28394)
Methods Study design: prospective, non blinded, randomised, controlled, multicentre, intervention study. To assess
whether catheter directed thrombolytic therapy for the treatment of IFDVT can safely and effectively reduce
post thrombotic morbidity after one year. The secondary objective is to study whether catheter directed
thrombolytic intervention has a positive effect on the quality of life of patients with IFDVT and to assess late
PTS
Participants The study population includes all consecutive patients with IFDVT presenting at the emergency or outpatient
departments of the participating centres. The thrombus should not be older than 14 days at randomisation
Interventions After randomisation patients will be allocated to either conservative anticoagulant treatment or to catheter
directed thrombolysis combined with conservative anticoagulant treatment
Outcomes The primary efficacy outcome is the incidence of PTS at one year; a decline in PTS incidence from 25% to
8% is anticipated. The secondary outcome is the Health related Quality of life and late PTS during follow-
up. The principal safety outcome is major bleeding during anticoagulant therapy. Bleeding as well as events
of recurrent thrombosis will be monitored. The patency of the venous system of the affected lower limb will
be assessed as well as the percentage of clot lysis, after thrombolytic intervention. Additionally, measurements
of markers of coagulation and inflammation will be performed during follow-up
Starting date May 2010
Contact information Rob Strijkers, MD
Notes NCT00970619
CDT: catheter-directed thrombolysis
DVT: deep vein thrombosis
IFDVT: ileofemoral deep vein thrombosis
INR: international normalised ratio
PTA: percutaneous transluminal angioplasty
PTS: post-thrombotic syndrome
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D A T A A N D A N A L Y S E S
Comparison 1. Any thrombolysis versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Any improvement in venous
patency (early)
9 421 Risk Ratio (M-H, Random, 95% CI) 2.48 [1.35, 4.57]
2 Complete clot lysis (early) 8 592 Risk Ratio (M-H, Random, 95% CI) 4.91 [1.66, 14.53]
3 Bleeding (early) 17 1103 Risk Ratio (M-H, Fixed, 95% CI) 2.23 [1.41, 3.52]
4 Stroke/intracerebral
haemorrhage (early)
17 1103 Risk Ratio (M-H, Fixed, 95% CI) 1.92 [0.34, 10.86]
5 Mortality (early) 9 529 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.31, 1.89]
6 Pulmonary embolism (early) 6 433 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.33, 3.05]
7 Post-thrombotic syndrome
(intermediate)
3 306 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.53, 0.81]
8 Post-thrombotic syndrome (late) 2 211 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.45, 0.77]
9 Leg ulceration (intermediate) 4 342 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.16, 4.73]
10 Leg ulceration (late) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
11 Complete clot lysis
(intermediate)
7 630 Risk Ratio (M-H, Random, 95% CI) 2.44 [1.40, 4.27]
12 Complete clot lysis (late) 2 206 Risk Ratio (M-H, Random, 95% CI) 3.25 [0.17, 62.63]
13 Mortality (intermediate) 2 289 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.27, 3.43]
14 Mortality (late) 2 230 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.25, 1.50]
15 Normal venous function
(intermediate)
3 255 Risk Ratio (M-H, Random, 95% CI) 2.18 [0.86, 5.54]
16 Recurrent DVT (intermediate) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 2. Systemic thrombolysis versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Any improvement in venous
patency (early)
8 386 Risk Ratio (M-H, Random, 95% CI) 2.18 [1.28, 3.70]
2 Complete clot lysis (early) 7 457 Risk Ratio (M-H, Random, 95% CI) 4.37 [1.40, 13.61]
3 Bleeding (early) 15 779 Risk Ratio (M-H, Fixed, 95% CI) 2.18 [1.37, 3.47]
4 Stroke/intracerebral
haemorrhage (early)
15 779 Risk Ratio (M-H, Fixed, 95% CI) 1.92 [0.34, 10.86]
5 Mortality (early) 8 394 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.31, 1.89]
6 Pulmonary embolism (early) 5 298 Risk Ratio (M-H, Fixed, 95% CI) 1.73 [0.55, 5.40]
7 Post-thrombotic syndrome
(intermediate)
2 117 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.30, 1.03]
8 Post-thrombotic syndrome (late) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
9 Leg ulceration (intermediate) 3 153 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.16, 4.73]
10 Leg ulceration (late) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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11 Complete clot lysis
(intermediate)
5 300 Risk Ratio (M-H, Random, 95% CI) 2.59 [1.27, 5.28]
12 Complete clot lysis (late) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
13 Mortality (intermediate) 2 189 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.27, 3.43]
14 Mortality (late) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
15 Normal venous function
(intermediate)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
16 Recurrent DVT (late) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 3. Loco-regional thrombolysis versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Complete clot lysis (early) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Bleeding (early) 2 146 Risk Ratio (M-H, Fixed, 95% CI) 4.0 [0.46, 34.75]
3 Stroke/intracerebral
haemorrhage (early)
2 146 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Mortality (early) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Pulmonary embolism (early) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Post-thrombotic syndrome
(intermediate)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7 Leg ulceration (intermediate) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
8 Complete clot lysis
(intermediate)
2 139 Risk Ratio (M-H, Fixed, 95% CI) 2.25 [1.33, 3.80]
9 Mortality (intermediate) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 4. Catheter-directed thrombolysis versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Any improvement in venous
patency (early)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Complete clot lysis (early) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Bleeding (early) 2 224 Risk Ratio (M-H, Fixed, 95% CI) 7.69 [0.40, 146.90]
4 Stroke/intracerebral
haemorrhage (early)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Mortality (early) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Pulmonary embolism (early) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7 Post-thrombotic syndrome
(intermediate)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
8 Post-thrombotic syndrome (late) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
9 Leg ulceration (intermediate) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
10 Complete clot lysis
(intermediate)
2 224 Risk Ratio (M-H, Random, 95% CI) 2.52 [0.52, 12.17]
11 Complete clot lysis (late) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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12 Normal venous function
(intermediate)
2 224 Risk Ratio (M-H, Fixed, 95% CI) 2.98 [1.75, 5.08]
13 Recurrent VTE (intermediate) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
14 Recurrent VTE (late) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
15 Mortality (late) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Any thrombolysis versus control, Outcome 1 Any improvement in venous
patency (early).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 1 Any thrombolysis versus control
Outcome: 1 Any improvement in venous patency (early)
Study or subgroup Thrombolysis
Standard
anticoagula-
tion Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Arneson 1978 15/21 5/21 13.4 % 3.00 [ 1.33, 6.75 ]
Common 1976 17/21 15/25 16.4 % 1.35 [ 0.92, 1.98 ]
Elsharawy 2002 18/18 0/17 3.9 % 35.05 [ 2.28, 539.63 ]
Goldhaber 1990 29/53 2/12 9.8 % 3.28 [ 0.90, 11.91 ]
Goldhaber 1996 6/8 6/9 14.9 % 1.13 [ 0.61, 2.07 ]
Kakkar 1969 7/9 4/9 13.4 % 1.75 [ 0.78, 3.93 ]
Kiil 1981 1/11 1/8 4.2 % 0.73 [ 0.05, 9.97 ]
Turpie 1990 22/40 9/42 14.7 % 2.57 [ 1.35, 4.88 ]
Ugurlu 2002 28/50 2/47 9.3 % 13.16 [ 3.32, 52.21 ]
Total (95% CI) 231 190 100.0 % 2.48 [ 1.35, 4.57 ]
Total events: 143 (Thrombolysis), 44 (Standard anticoagulation)
Heterogeneity: Tau2 = 0.55; Chi2 = 34.37, df = 8 (P = 0.00003); I2 =77%
Test for overall effect: Z = 2.92 (P = 0.0035)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
favours anticoagulation favours thrombolysis
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Analysis 1.2. Comparison 1 Any thrombolysis versus control, Outcome 2 Complete clot lysis (early).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 1 Any thrombolysis versus control
Outcome: 2 Complete clot lysis (early)
Study or subgroup Thrombolysis
Standard
anticoagula-
tion Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Common 1976 6/23 1/26 12.7 % 6.78 [ 0.88, 52.23 ]
Elliot 1979 9/26 0/25 9.1 % 18.30 [ 1.12, 298.59 ]
Elsharawy 2002 11/18 0/17 9.3 % 21.79 [ 1.38, 343.26 ]
Goldhaber 1990 3/53 0/12 8.7 % 1.69 [ 0.09, 30.65 ]
Kakkar 1969 6/9 2/9 17.3 % 3.00 [ 0.81, 11.08 ]
Schulman 1986 8/14 6/13 20.9 % 1.24 [ 0.59, 2.60 ]
Schweizer 2000 57/200 1/50 13.2 % 14.25 [ 2.02, 100.42 ]
Ugurlu 2002 3/50 0/47 8.6 % 6.59 [ 0.35, 124.23 ]
Total (95% CI) 393 199 100.0 % 4.91 [ 1.66, 14.53 ]
Total events: 103 (Thrombolysis), 10 (Standard anticoagulation)
Heterogeneity: Tau2 = 1.32; Chi2 = 18.56, df = 7 (P = 0.01); I2 =62%
Test for overall effect: Z = 2.87 (P = 0.0041)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
favours anticoagulation favours thrombolysis
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Analysis 1.3. Comparison 1 Any thrombolysis versus control, Outcome 3 Bleeding (early).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 1 Any thrombolysis versus control
Outcome: 3 Bleeding (early)
Study or subgroup Thrombolysis
Standard
anticoagula-
tion Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arneson 1978 4/21 4/21 16.6 % 1.00 [ 0.29, 3.48 ]
Common 1976 7/23 5/26 19.4 % 1.58 [ 0.58, 4.31 ]
Elliot 1979 3/26 0/25 2.1 % 6.74 [ 0.37, 124.21 ]
Elsharawy 2002 0/18 0/17 Not estimable
Enden 2011 3/90 0/99 2.0 % 7.69 [ 0.40, 146.90 ]
Goldhaber 1990 2/53 0/12 3.3 % 1.20 [ 0.06, 23.59 ]
Goldhaber 1996 0/8 1/9 5.9 % 0.37 [ 0.02, 7.99 ]
Kakkar 1969 4/10 2/9 8.7 % 1.80 [ 0.43, 7.59 ]
Kiil 1981 3/11 3/8 14.4 % 0.73 [ 0.20, 2.71 ]
Marder 1977 7/15 1/12 4.6 % 5.60 [ 0.79, 39.48 ]
Schulman 1986 3/17 1/19 3.9 % 3.35 [ 0.38, 29.26 ]
Schweizer 1998 4/46 0/23 2.7 % 4.60 [ 0.26, 81.88 ]
Schweizer 2000 12/200 0/50 3.3 % 6.34 [ 0.38, 105.36 ]
Tsapogas 1973 0/19 0/15 Not estimable
Turpie 1990 5/41 2/42 8.2 % 2.56 [ 0.53, 12.46 ]
Ugurlu 2002 2/50 0/47 2.1 % 4.71 [ 0.23, 95.53 ]
Verhaeghe 1989 3/14 0/7 2.7 % 3.73 [ 0.22, 63.66 ]
Total (95% CI) 662 441 100.0 % 2.23 [ 1.41, 3.52 ]
Total events: 62 (Thrombolysis), 19 (Standard anticoagulation)
Heterogeneity: Chi2 = 9.76, df = 14 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 3.42 (P = 0.00064)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
favours thrombolysis favours anticoagulation
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Analysis 1.4. Comparison 1 Any thrombolysis versus control, Outcome 4 Stroke/intracerebral
haemorrhage (early).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 1 Any thrombolysis versus control
Outcome: 4 Stroke/intracerebral haemorrhage (early)
Study or subgroup Thrombolysis
Standard
anticoagula-
tion Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arneson 1978 0/21 0/21 Not estimable
Common 1976 1/23 0/26 25.7 % 3.38 [ 0.14, 79.00 ]
Elliot 1979 0/26 0/25 Not estimable
Elsharawy 2002 0/18 0/17 Not estimable
Enden 2011 0/90 0/99 Not estimable
Goldhaber 1990 1/53 0/12 44.1 % 0.72 [ 0.03, 16.73 ]
Goldhaber 1996 0/8 0/9 Not estimable
Kakkar 1969 0/10 0/9 Not estimable
Kiil 1981 0/11 0/8 Not estimable
Marder 1977 1/15 0/12 30.2 % 2.44 [ 0.11, 54.97 ]
Schulman 1986 0/17 0/19 Not estimable
Schweizer 1998 0/46 0/23 Not estimable
Schweizer 2000 0/200 0/50 Not estimable
Tsapogas 1973 0/19 0/15 Not estimable
Turpie 1990 0/41 0/42 Not estimable
Ugurlu 2002 0/50 0/47 Not estimable
Verhaeghe 1989 0/14 0/7 Not estimable
Total (95% CI) 662 441 100.0 % 1.92 [ 0.34, 10.86 ]
Total events: 3 (Thrombolysis), 0 (Standard anticoagulation)
Heterogeneity: Chi2 = 0.52, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
favours thrombolysis favours anticoagulation
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Analysis 1.5. Comparison 1 Any thrombolysis versus control, Outcome 5 Mortality (early).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 1 Any thrombolysis versus control
Outcome: 5 Mortality (early)
Study or subgroup Thrombolysis
Standard
anticoagula-
tion Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arneson 1978 0/21 1/21 15.4 % 0.33 [ 0.01, 7.74 ]
Common 1976 1/23 0/26 4.8 % 3.38 [ 0.14, 79.00 ]
Elliot 1979 0/26 2/25 26.2 % 0.19 [ 0.01, 3.82 ]
Elsharawy 2002 0/18 0/17 Not estimable
Kakkar 1969 2/10 2/10 20.6 % 1.00 [ 0.17, 5.77 ]
Kiil 1981 0/11 1/8 17.6 % 0.25 [ 0.01, 5.45 ]
Marder 1977 1/15 0/12 5.7 % 2.44 [ 0.11, 54.97 ]
Schulman 1986 1/17 1/19 9.7 % 1.12 [ 0.08, 16.52 ]
Schweizer 2000 0/200 0/50 Not estimable
Total (95% CI) 341 188 100.0 % 0.76 [ 0.31, 1.89 ]
Total events: 5 (Thrombolysis), 7 (Standard anticoagulation)
Heterogeneity: Chi2 = 3.14, df = 6 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.56)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
favours thrombolysis favours anticoagulation
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Analysis 1.6. Comparison 1 Any thrombolysis versus control, Outcome 6 Pulmonary embolism (early).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 1 Any thrombolysis versus control
Outcome: 6 Pulmonary embolism (early)
Study or subgroup Thrombolysis
Standard
anticoagula-
tion Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arneson 1978 1/21 1/21 14.7 % 1.00 [ 0.07, 14.95 ]
Elsharawy 2002 0/18 1/17 22.6 % 0.32 [ 0.01, 7.26 ]
Elliot 1979 1/26 2/25 30.0 % 0.48 [ 0.05, 4.98 ]
Kakkar 1969 0/9 1/10 21.0 % 0.37 [ 0.02, 8.01 ]
Schulman 1986 0/17 0/19 Not estimable
Schweizer 2000 9/200 0/50 11.7 % 4.82 [ 0.29, 81.46 ]
Total (95% CI) 291 142 100.0 % 1.00 [ 0.33, 3.05 ]
Total events: 11 (Thrombolysis), 5 (Standard anticoagulation)
Heterogeneity: Chi2 = 2.50, df = 4 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours thrombolysis favours anticoagulation
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Analysis 1.7. Comparison 1 Any thrombolysis versus control, Outcome 7 Post-thrombotic syndrome
(intermediate).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 1 Any thrombolysis versus control
Outcome: 7 Post-thrombotic syndrome (intermediate)
Study or subgroup Thrombolysis
Standard
anticoagula-
tion Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elliot 1979 10/26 24/25 24.6 % 0.40 [ 0.24, 0.66 ]
Enden 2011 37/90 55/99 52.6 % 0.74 [ 0.55, 1.00 ]
Schweizer 1998 25/44 17/22 22.8 % 0.74 [ 0.52, 1.04 ]
Total (95% CI) 160 146 100.0 % 0.66 [ 0.53, 0.81 ]
Total events: 72 (Thrombolysis), 96 (Standard anticoagulation)
Heterogeneity: Chi2 = 4.88, df = 2 (P = 0.09); I2 =59%
Test for overall effect: Z = 3.92 (P = 0.000089)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
favours thrombolysis favours anticoagulation
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Analysis 1.8. Comparison 1 Any thrombolysis versus control, Outcome 8 Post-thrombotic syndrome (late).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 1 Any thrombolysis versus control
Outcome: 8 Post-thrombotic syndrome (late)
Study or subgroup Thrombolysis
Standard
anticoagula-
tion Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arneson 1978 4/17 9/18 12.3 % 0.47 [ 0.18, 1.25 ]
Enden 2011 37/87 63/89 87.7 % 0.60 [ 0.45, 0.79 ]
Total (95% CI) 104 107 100.0 % 0.58 [ 0.45, 0.77 ]
Total events: 41 (Thrombolysis), 72 (Standard anticoagulation)
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 3.90 (P = 0.000097)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
favours thrombolysis favours anticoagulation
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Analysis 1.9. Comparison 1 Any thrombolysis versus control, Outcome 9 Leg ulceration (intermediate).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 1 Any thrombolysis versus control
Outcome: 9 Leg ulceration (intermediate)
Study or subgroup Thrombolysis
Standard
anticoagula-
tion Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elliot 1979 0/26 1/25 53.4 % 0.32 [ 0.01, 7.53 ]
Enden 2011 0/90 0/99 Not estimable
Schulman 1986 0/17 0/19 Not estimable
Schweizer 1998 3/44 1/22 46.6 % 1.50 [ 0.17, 13.60 ]
Total (95% CI) 177 165 100.0 % 0.87 [ 0.16, 4.73 ]
Total events: 3 (Thrombolysis), 2 (Standard anticoagulation)
Heterogeneity: Chi2 = 0.62, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
favours thrombolysis favours anticoagulation
Analysis 1.10. Comparison 1 Any thrombolysis versus control, Outcome 10 Leg ulceration (late).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 1 Any thrombolysis versus control
Outcome: 10 Leg ulceration (late)
Study or subgroup Thrombolysis
Standard
anticoagula-
tion Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arneson 1978 0/17 3/18 0.15 [ 0.01, 2.72 ]
0.001 0.01 0.1 1 10 100 1000
favours thrombolysis favours anticoagulation
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Analysis 1.11. Comparison 1 Any thrombolysis versus control, Outcome 11 Complete clot lysis
(intermediate).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 1 Any thrombolysis versus control
Outcome: 11 Complete clot lysis (intermediate)
Study or subgroup Thrombolysis
Standard
anticoagula-
tion Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Common 1976 6/15 1/12 6.1 % 4.80 [ 0.67, 34.63 ]
Elliot 1979 (1) 12/26 0/25 3.5 % 24.07 [ 1.50, 386.09 ]
Elsharawy 2002 13/18 2/17 10.5 % 6.14 [ 1.62, 23.28 ]
Enden 2011 (2) 68/90 56/99 25.4 % 1.34 [ 1.08, 1.65 ]
Schulman 1986 (3) 11/17 6/19 17.9 % 2.05 [ 0.97, 4.33 ]
Schweizer 1998 27/44 8/22 20.2 % 1.69 [ 0.93, 3.08 ]
Schweizer 2000 61/180 5/46 16.3 % 3.12 [ 1.33, 7.31 ]
Total (95% CI) 390 240 100.0 % 2.44 [ 1.40, 4.27 ]
Total events: 198 (Thrombolysis), 78 (Standard anticoagulation)
Heterogeneity: Tau2 = 0.31; Chi2 = 19.92, df = 6 (P = 0.003); I2 =70%
Test for overall effect: Z = 3.13 (P = 0.0017)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
favours anticoagulation favours thrombolysis
(1) control result for Elliot, entered as 2 in previous versions, reviewed as 0
(2) 24 months
(3) 12 month data
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Analysis 1.12. Comparison 1 Any thrombolysis versus control, Outcome 12 Complete clot lysis (late).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 1 Any thrombolysis versus control
Outcome: 12 Complete clot lysis (late)
Study or subgroup Thrombolysis
Standard
anticoagula-
tion Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Arneson 1978 (1) 7/16 0/18 39.4 % 16.76 [ 1.03, 272.11 ]
Enden 2011 (2) 68/86 61/86 60.6 % 1.11 [ 0.94, 1.33 ]
Total (95% CI) 102 104 100.0 % 3.25 [ 0.17, 62.63 ]
Total events: 75 (Thrombolysis), 61 (Standard anticoagulation)
Heterogeneity: Tau2 = 3.76; Chi2 = 4.70, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
favours anticoagulation favours thrombolysis
(1) mean follow up 6.5 years
(2) Four patients had inconclusive results and not reported.
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Analysis 1.13. Comparison 1 Any thrombolysis versus control, Outcome 13 Mortality (intermediate).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 1 Any thrombolysis versus control
Outcome: 13 Mortality (intermediate)
Study or subgroup Thrombolysis
Standard
anticoagula-
tion Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elliot 1979 4/26 4/25 100.0 % 0.96 [ 0.27, 3.43 ]
Schweizer 2000 0/192 0/46 Not estimable
Total (95% CI) 218 71 100.0 % 0.96 [ 0.27, 3.43 ]
Total events: 4 (Thrombolysis), 4 (Standard anticoagulation)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
favours thrombolysis favours anticoagulation
Analysis 1.14. Comparison 1 Any thrombolysis versus control, Outcome 14 Mortality (late).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 1 Any thrombolysis versus control
Outcome: 14 Mortality (late)
Study or subgroup Thrombolysis
Standard
anticoagula-
tion Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arneson 1978 4/21 3/21 25.8 % 1.33 [ 0.34, 5.24 ]
Enden 2011 3/90 9/98 74.2 % 0.36 [ 0.10, 1.30 ]
Total (95% CI) 111 119 100.0 % 0.61 [ 0.25, 1.50 ]
Total events: 7 (Thrombolysis), 12 (Standard anticoagulation)
Heterogeneity: Chi2 = 1.89, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 1.07 (P = 0.28)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
favours thrombolysis favours anticoagulation
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Analysis 1.15. Comparison 1 Any thrombolysis versus control, Outcome 15 Normal venous function
(intermediate).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 1 Any thrombolysis versus control
Outcome: 15 Normal venous function (intermediate)
Study or subgroup Thrombolysis
Standard
anticoagula-
tion Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Elsharawy 2002 13/18 2/17 23.4 % 6.14 [ 1.62, 23.28 ]
Enden 2011 29/90 13/99 38.0 % 2.45 [ 1.36, 4.42 ]
Schulman 1986 10/16 9/15 38.6 % 1.04 [ 0.59, 1.83 ]
Total (95% CI) 124 131 100.0 % 2.18 [ 0.86, 5.54 ]
Total events: 52 (Thrombolysis), 24 (Standard anticoagulation)
Heterogeneity: Tau2 = 0.50; Chi2 = 9.34, df = 2 (P = 0.01); I2 =79%
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours anticoagulation favours thrombolysis
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Analysis 1.16. Comparison 1 Any thrombolysis versus control, Outcome 16 Recurrent DVT (intermediate).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 1 Any thrombolysis versus control
Outcome: 16 Recurrent DVT (intermediate)
Study or subgroup Thrombolysis
Standard
anticoagula-
tion Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arneson 1978 4/17 3/18 1.41 [ 0.37, 5.40 ]
0.1 0.2 0.5 1 2 5 10
favours thrombolysis favours anticoagulation
Analysis 2.1. Comparison 2 Systemic thrombolysis versus control, Outcome 1 Any improvement in venous
patency (early).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 2 Systemic thrombolysis versus control
Outcome: 1 Any improvement in venous patency (early)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Arneson 1978 15/21 5/21 13.9 % 3.00 [ 1.33, 6.75 ]
Common 1976 17/21 15/25 18.7 % 1.35 [ 0.92, 1.98 ]
Goldhaber 1990 29/53 2/12 9.3 % 3.28 [ 0.90, 11.91 ]
Goldhaber 1996 6/8 6/9 16.2 % 1.13 [ 0.61, 2.07 ]
Kakkar 1969 7/9 4/9 14.0 % 1.75 [ 0.78, 3.93 ]
Kiil 1981 1/11 1/8 3.4 % 0.73 [ 0.05, 9.97 ]
Turpie 1990 22/40 9/42 15.8 % 2.57 [ 1.35, 4.88 ]
Ugurlu 2002 28/50 2/47 8.6 % 13.16 [ 3.32, 52.21 ]
0.001 0.01 0.1 1 10 100 1000
favours anticoagulation favours thrombolysis
(Continued . . . )
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(. . . Continued)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total (95% CI) 213 173 100.0 % 2.18 [ 1.28, 3.70 ]
Total events: 125 (Thrombolysis), 44 (Standard anticoagulant)
Heterogeneity: Tau2 = 0.36; Chi2 = 23.77, df = 7 (P = 0.001); I2 =71%
Test for overall effect: Z = 2.87 (P = 0.0041)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
favours anticoagulation favours thrombolysis
Analysis 2.2. Comparison 2 Systemic thrombolysis versus control, Outcome 2 Complete clot lysis (early).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 2 Systemic thrombolysis versus control
Outcome: 2 Complete clot lysis (early)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Common 1976 6/23 1/26 14.0 % 6.78 [ 0.88, 52.23 ]
Elliot 1979 9/26 0/25 10.1 % 18.30 [ 1.12, 298.59 ]
Goldhaber 1990 3/53 0/12 9.6 % 1.69 [ 0.09, 30.65 ]
Kakkar 1969 6/9 2/9 19.2 % 3.00 [ 0.81, 11.08 ]
Schulman 1986 8/14 6/13 23.1 % 1.24 [ 0.59, 2.60 ]
Schweizer 2000 37/100 1/50 14.6 % 18.50 [ 2.61, 130.95 ]
Ugurlu 2002 3/50 0/47 9.5 % 6.59 [ 0.35, 124.23 ]
Total (95% CI) 275 182 100.0 % 4.37 [ 1.40, 13.61 ]
Total events: 72 (Thrombolysis), 10 (Standard anticoagulant)
Heterogeneity: Tau2 = 1.31; Chi2 = 16.57, df = 6 (P = 0.01); I2 =64%
Test for overall effect: Z = 2.54 (P = 0.011)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
favours anticoagulation favours thrombolysis
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Analysis 2.3. Comparison 2 Systemic thrombolysis versus control, Outcome 3 Bleeding (early).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 2 Systemic thrombolysis versus control
Outcome: 3 Bleeding (early)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arneson 1978 4/21 4/21 17.0 % 1.00 [ 0.29, 3.48 ]
Common 1976 7/23 5/26 19.9 % 1.58 [ 0.58, 4.31 ]
Elliot 1979 3/26 0/25 2.2 % 6.74 [ 0.37, 124.21 ]
Goldhaber 1990 2/53 0/12 3.4 % 1.20 [ 0.06, 23.59 ]
Goldhaber 1996 0/8 1/9 6.0 % 0.37 [ 0.02, 7.99 ]
Kakkar 1969 4/10 2/9 8.9 % 1.80 [ 0.43, 7.59 ]
Kiil 1981 3/11 3/8 14.8 % 0.73 [ 0.20, 2.71 ]
Marder 1977 7/15 1/12 4.7 % 5.60 [ 0.79, 39.48 ]
Schulman 1986 3/17 1/19 4.0 % 3.35 [ 0.38, 29.26 ]
Schweizer 1998 4/46 0/23 2.8 % 4.60 [ 0.26, 81.88 ]
Schweizer 2000 9/100 0/50 2.8 % 9.59 [ 0.57, 161.57 ]
Tsapogas 1973 0/19 0/15 Not estimable
Turpie 1990 5/41 2/42 8.4 % 2.56 [ 0.53, 12.46 ]
Ugurlu 2002 2/50 0/47 2.2 % 4.71 [ 0.23, 95.53 ]
Verhaeghe 1989 3/14 0/7 2.8 % 3.73 [ 0.22, 63.66 ]
Total (95% CI) 454 325 100.0 % 2.18 [ 1.37, 3.47 ]
Total events: 56 (Thrombolysis), 19 (Standard anticoagulant)
Heterogeneity: Chi2 = 9.45, df = 13 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 3.30 (P = 0.00097)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
favours thrombolysis favours anticoagulation
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Analysis 2.4. Comparison 2 Systemic thrombolysis versus control, Outcome 4 Stroke/intracerebral
haemorrhage (early).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 2 Systemic thrombolysis versus control
Outcome: 4 Stroke/intracerebral haemorrhage (early)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arneson 1978 0/21 0/21 Not estimable
Common 1976 1/23 0/26 25.7 % 3.38 [ 0.14, 79.00 ]
Elliot 1979 0/26 0/25 Not estimable
Goldhaber 1990 1/53 0/12 44.1 % 0.72 [ 0.03, 16.73 ]
Goldhaber 1996 0/8 0/9 Not estimable
Kakkar 1969 0/10 0/9 Not estimable
Kiil 1981 0/11 0/8 Not estimable
Marder 1977 1/15 0/12 30.2 % 2.44 [ 0.11, 54.97 ]
Schulman 1986 0/17 0/19 Not estimable
Schweizer 1998 0/46 0/23 Not estimable
Schweizer 2000 0/100 0/50 Not estimable
Tsapogas 1973 0/19 0/15 Not estimable
Turpie 1990 0/41 0/42 Not estimable
Ugurlu 2002 0/50 0/47 Not estimable
Verhaeghe 1989 0/14 0/7 Not estimable
Total (95% CI) 454 325 100.0 % 1.92 [ 0.34, 10.86 ]
Total events: 3 (Thrombolysis), 0 (Standard anticoagulant)
Heterogeneity: Chi2 = 0.52, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
favours thrombolysis favours anticoagulation
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Analysis 2.5. Comparison 2 Systemic thrombolysis versus control, Outcome 5 Mortality (early).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 2 Systemic thrombolysis versus control
Outcome: 5 Mortality (early)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arneson 1978 0/21 1/21 15.4 % 0.33 [ 0.01, 7.74 ]
Common 1976 1/23 0/26 4.8 % 3.38 [ 0.14, 79.00 ]
Elliot 1979 0/26 2/25 26.2 % 0.19 [ 0.01, 3.82 ]
Kakkar 1969 2/10 2/10 20.6 % 1.00 [ 0.17, 5.77 ]
Kiil 1981 0/11 1/8 17.6 % 0.25 [ 0.01, 5.45 ]
Marder 1977 1/15 0/12 5.7 % 2.44 [ 0.11, 54.97 ]
Schulman 1986 1/17 1/19 9.7 % 1.12 [ 0.08, 16.52 ]
Schweizer 2000 0/100 0/50 Not estimable
Total (95% CI) 223 171 100.0 % 0.76 [ 0.31, 1.89 ]
Total events: 5 (Thrombolysis), 7 (Standard anticoagulant)
Heterogeneity: Chi2 = 3.14, df = 6 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.56)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
favours thrombolysis favours anticoagulation
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Analysis 2.6. Comparison 2 Systemic thrombolysis versus control, Outcome 6 Pulmonary embolism (early).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 2 Systemic thrombolysis versus control
Outcome: 6 Pulmonary embolism (early)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arneson 1978 1/21 1/21 19.5 % 1.00 [ 0.07, 14.95 ]
Elliot 1979 1/26 2/25 39.7 % 0.48 [ 0.05, 4.98 ]
Kakkar 1969 0/9 1/10 27.8 % 0.37 [ 0.02, 8.01 ]
Schulman 1986 0/17 0/19 Not estimable
Schweizer 2000 9/100 0/50 12.9 % 9.59 [ 0.57, 161.57 ]
Total (95% CI) 173 125 100.0 % 1.73 [ 0.55, 5.40 ]
Total events: 11 (Thrombolysis), 4 (Standard anticoagulant)
Heterogeneity: Chi2 = 3.70, df = 3 (P = 0.30); I2 =19%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
favours thrombolysis favours anticoagulation
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Analysis 2.7. Comparison 2 Systemic thrombolysis versus control, Outcome 7 Post-thrombotic syndrome
(intermediate).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 2 Systemic thrombolysis versus control
Outcome: 7 Post-thrombotic syndrome (intermediate)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Elliot 1979 10/26 24/25 45.8 % 0.40 [ 0.24, 0.66 ]
Schweizer 1998 25/44 17/22 54.2 % 0.74 [ 0.52, 1.04 ]
Total (95% CI) 70 47 100.0 % 0.56 [ 0.30, 1.03 ]
Total events: 35 (Thrombolysis), 41 (Standard anticoagulant)
Heterogeneity: Tau2 = 0.15; Chi2 = 4.17, df = 1 (P = 0.04); I2 =76%
Test for overall effect: Z = 1.88 (P = 0.060)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
favours thrombolysis favours anticoagulation
Analysis 2.8. Comparison 2 Systemic thrombolysis versus control, Outcome 8 Post-thrombotic syndrome
(late).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 2 Systemic thrombolysis versus control
Outcome: 8 Post-thrombotic syndrome (late)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arneson 1978 4/17 9/18 0.47 [ 0.18, 1.25 ]
0.1 0.2 0.5 1 2 5 10
favours thrombolysis favours anticoagulation
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Analysis 2.9. Comparison 2 Systemic thrombolysis versus control, Outcome 9 Leg ulceration
(intermediate).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 2 Systemic thrombolysis versus control
Outcome: 9 Leg ulceration (intermediate)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elliot 1979 0/26 1/25 53.4 % 0.32 [ 0.01, 7.53 ]
Schulman 1986 0/17 0/19 Not estimable
Schweizer 1998 3/44 1/22 46.6 % 1.50 [ 0.17, 13.60 ]
Total (95% CI) 87 66 100.0 % 0.87 [ 0.16, 4.73 ]
Total events: 3 (Thrombolysis), 2 (Standard anticoagulant)
Heterogeneity: Chi2 = 0.62, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
favours thrombolysis favours anticoagulation
Analysis 2.10. Comparison 2 Systemic thrombolysis versus control, Outcome 10 Leg ulceration (late).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 2 Systemic thrombolysis versus control
Outcome: 10 Leg ulceration (late)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arneson 1978 0/17 3/18 0.15 [ 0.01, 2.72 ]
0.001 0.01 0.1 1 10 100 1000
favours thrombolysis favours anticoagulation
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Analysis 2.11. Comparison 2 Systemic thrombolysis versus control, Outcome 11 Complete clot lysis
(intermediate).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 2 Systemic thrombolysis versus control
Outcome: 11 Complete clot lysis (intermediate)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Common 1976 6/15 1/12 9.7 % 4.80 [ 0.67, 34.63 ]
Elliot 1979 (1) 12/26 0/25 5.6 % 24.07 [ 1.50, 386.09 ]
Schulman 1986 11/15 6/12 29.5 % 1.47 [ 0.77, 2.79 ]
Schweizer 1998 27/44 8/22 30.4 % 1.69 [ 0.93, 3.08 ]
Schweizer 2000 37/83 5/46 24.7 % 4.10 [ 1.73, 9.71 ]
Total (95% CI) 183 117 100.0 % 2.59 [ 1.27, 5.28 ]
Total events: 93 (Thrombolysis), 20 (Standard anticoagulant)
Heterogeneity: Tau2 = 0.34; Chi2 = 10.12, df = 4 (P = 0.04); I2 =60%
Test for overall effect: Z = 2.62 (P = 0.0087)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
favours anticoagulation favours thrombolysis
(1) Control events changed to 1
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Analysis 2.12. Comparison 2 Systemic thrombolysis versus control, Outcome 12 Complete clot lysis (late).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 2 Systemic thrombolysis versus control
Outcome: 12 Complete clot lysis (late)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arneson 1978 (1) 7/16 0/18 16.76 [ 1.03, 272.11 ]
0.001 0.01 0.1 1 10 100 1000
favours anticoagulation favours thrombolysis
(1) Results reported at mean of 6.5 years.
Analysis 2.13. Comparison 2 Systemic thrombolysis versus control, Outcome 13 Mortality (intermediate).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 2 Systemic thrombolysis versus control
Outcome: 13 Mortality (intermediate)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elliot 1979 4/26 4/25 100.0 % 0.96 [ 0.27, 3.43 ]
Schweizer 2000 0/92 0/46 Not estimable
Total (95% CI) 118 71 100.0 % 0.96 [ 0.27, 3.43 ]
Total events: 4 (Thrombolysis), 4 (Standard anticoagulant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
favours thrombolysis favours anticoagulation
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Analysis 2.14. Comparison 2 Systemic thrombolysis versus control, Outcome 14 Mortality (late).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 2 Systemic thrombolysis versus control
Outcome: 14 Mortality (late)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arneson 1978 4/21 3/21 1.33 [ 0.34, 5.24 ]
0.1 0.2 0.5 1 2 5 10
favours thrombolysis favours anticoagulation
Analysis 2.15. Comparison 2 Systemic thrombolysis versus control, Outcome 15 Normal venous function
(intermediate).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 2 Systemic thrombolysis versus control
Outcome: 15 Normal venous function (intermediate)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schulman 1986 10/16 9/15 1.04 [ 0.59, 1.83 ]
0.01 0.1 1 10 100
favours anticoagulation favours thrombolysis
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Analysis 2.16. Comparison 2 Systemic thrombolysis versus control, Outcome 16 Recurrent DVT (late).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 2 Systemic thrombolysis versus control
Outcome: 16 Recurrent DVT (late)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arneson 1978 4/17 3/18 1.41 [ 0.37, 5.40 ]
0.1 0.2 0.5 1 2 5 10
favours thrombolysis favours anticoagulation
Analysis 3.1. Comparison 3 Loco-regional thrombolysis versus control, Outcome 1 Complete clot lysis
(early).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 3 Loco-regional thrombolysis versus control
Outcome: 1 Complete clot lysis (early)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schweizer 2000 10/50 1/50 10.00 [ 1.33, 75.23 ]
0.01 0.1 1 10 100
favours anticoagulation favours thrombolysis
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Analysis 3.2. Comparison 3 Loco-regional thrombolysis versus control, Outcome 2 Bleeding (early).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 3 Loco-regional thrombolysis versus control
Outcome: 2 Bleeding (early)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schweizer 1998 2/23 0/23 50.0 % 5.00 [ 0.25, 98.75 ]
Schweizer 2000 1/50 0/50 50.0 % 3.00 [ 0.13, 71.92 ]
Total (95% CI) 73 73 100.0 % 4.00 [ 0.46, 34.75 ]
Total events: 3 (Thrombolysis), 0 (Standard anticoagulant)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours thrombolysis favours anticoagulation
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Analysis 3.3. Comparison 3 Loco-regional thrombolysis versus control, Outcome 3 Stroke/intracerebral
haemorrhage (early).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 3 Loco-regional thrombolysis versus control
Outcome: 3 Stroke/intracerebral haemorrhage (early)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schweizer 1998 0/23 0/23 Not estimable
Schweizer 2000 0/50 0/50 Not estimable
Total (95% CI) 73 73 Not estimable
Total events: 0 (Thrombolysis), 0 (Standard anticoagulant)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours thrombolysis favours anticoagulation
Analysis 3.4. Comparison 3 Loco-regional thrombolysis versus control, Outcome 4 Mortality (early).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 3 Loco-regional thrombolysis versus control
Outcome: 4 Mortality (early)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schweizer 2000 0/50 0/50 Not estimable
0.1 0.2 0.5 1 2 5 10
favours thrombolysis favours anticoagulation
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Analysis 3.5. Comparison 3 Loco-regional thrombolysis versus control, Outcome 5 Pulmonary embolism
(early).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 3 Loco-regional thrombolysis versus control
Outcome: 5 Pulmonary embolism (early)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schweizer 2000 0/50 0/50 Not estimable
0.1 0.2 0.5 1 2 5 10
favours thrombolysis favours anticoagulation
Analysis 3.6. Comparison 3 Loco-regional thrombolysis versus control, Outcome 6 Post-thrombotic
syndrome (intermediate).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 3 Loco-regional thrombolysis versus control
Outcome: 6 Post-thrombotic syndrome (intermediate)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schweizer 1998 11/22 17/22 0.65 [ 0.40, 1.04 ]
0.1 0.2 0.5 1 2 5 10
favours thrombolysis favours anticoagulation
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Analysis 3.7. Comparison 3 Loco-regional thrombolysis versus control, Outcome 7 Leg ulceration
(intermediate).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 3 Loco-regional thrombolysis versus control
Outcome: 7 Leg ulceration (intermediate)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schweizer 1998 1/22 1/22 1.00 [ 0.07, 15.00 ]
0.01 0.1 1 10 100
favours thrombolysis favours anticoagulation
Analysis 3.8. Comparison 3 Loco-regional thrombolysis versus control, Outcome 8 Complete clot lysis
(intermediate).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 3 Loco-regional thrombolysis versus control
Outcome: 8 Complete clot lysis (intermediate)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schweizer 1998 17/22 8/22 60.8 % 2.13 [ 1.17, 3.86 ]
Schweizer 2000 13/49 5/46 39.2 % 2.44 [ 0.94, 6.31 ]
Total (95% CI) 71 68 100.0 % 2.25 [ 1.33, 3.80 ]
Total events: 30 (Thrombolysis), 13 (Standard anticoagulant)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 3.03 (P = 0.0025)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
favours anticoagulation favours thrombolysis
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Analysis 3.9. Comparison 3 Loco-regional thrombolysis versus control, Outcome 9 Mortality
(intermediate).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 3 Loco-regional thrombolysis versus control
Outcome: 9 Mortality (intermediate)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schweizer 2000 0/50 0/46 Not estimable
0.1 0.2 0.5 1 2 5 10
favours thrombolysis favours anticoagulation
Analysis 4.1. Comparison 4 Catheter-directed thrombolysis versus control, Outcome 1 Any improvement
in venous patency (early).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 4 Catheter-directed thrombolysis versus control
Outcome: 1 Any improvement in venous patency (early)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elsharawy 2002 18/18 0/17 35.05 [ 2.28, 539.63 ]
0.001 0.01 0.1 1 10 100 1000
favours anticoagulation favours thrombolysis
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Analysis 4.2. Comparison 4 Catheter-directed thrombolysis versus control, Outcome 2 Complete clot lysis
(early).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 4 Catheter-directed thrombolysis versus control
Outcome: 2 Complete clot lysis (early)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elsharawy 2002 11/18 0/17 21.79 [ 1.38, 343.26 ]
0.001 0.01 0.1 1 10 100 1000
favours anticoagulation favours thrombolysis
Analysis 4.3. Comparison 4 Catheter-directed thrombolysis versus control, Outcome 3 Bleeding (early).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 4 Catheter-directed thrombolysis versus control
Outcome: 3 Bleeding (early)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elsharawy 2002 0/18 0/17 Not estimable
Enden 2011 3/90 0/99 100.0 % 7.69 [ 0.40, 146.90 ]
Total (95% CI) 108 116 100.0 % 7.69 [ 0.40, 146.90 ]
Total events: 3 (Thrombolysis), 0 (Standard anticoagulant)
Heterogeneity: not applicable
Test for overall effect: Z = 1.36 (P = 0.18)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
favours thrombolysis favours anticoagulation
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Analysis 4.4. Comparison 4 Catheter-directed thrombolysis versus control, Outcome 4
Stroke/intracerebral haemorrhage (early).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 4 Catheter-directed thrombolysis versus control
Outcome: 4 Stroke/intracerebral haemorrhage (early)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elsharawy 2002 0/18 0/17 Not estimable
0.1 0.2 0.5 1 2 5 10
favours thrombolysis favours anticoagulation
Analysis 4.5. Comparison 4 Catheter-directed thrombolysis versus control, Outcome 5 Mortality (early).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 4 Catheter-directed thrombolysis versus control
Outcome: 5 Mortality (early)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elsharawy 2002 0/18 0/17 Not estimable
0.1 0.2 0.5 1 2 5 10
favours thrombolysis favours anticoagulation
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Analysis 4.6. Comparison 4 Catheter-directed thrombolysis versus control, Outcome 6 Pulmonary
embolism (early).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 4 Catheter-directed thrombolysis versus control
Outcome: 6 Pulmonary embolism (early)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elsharawy 2002 0/18 1/17 0.32 [ 0.01, 7.26 ]
0.01 0.1 1 10 100
favours thrombolysis favours anticoagulation
Analysis 4.7. Comparison 4 Catheter-directed thrombolysis versus control, Outcome 7 Post-thrombotic
syndrome (intermediate).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 4 Catheter-directed thrombolysis versus control
Outcome: 7 Post-thrombotic syndrome (intermediate)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Enden 2011 37/90 55/99 0.74 [ 0.55, 1.00 ]
0.01 0.1 1 10 100
favours thrombolysis favours anticoagulation
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Analysis 4.8. Comparison 4 Catheter-directed thrombolysis versus control, Outcome 8 Post-thrombotic
syndrome (late).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 4 Catheter-directed thrombolysis versus control
Outcome: 8 Post-thrombotic syndrome (late)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Enden 2011 37/87 63/89 0.60 [ 0.45, 0.79 ]
0.1 0.2 0.5 1 2 5 10
favours thrombolysis favours anticoagulation
Analysis 4.9. Comparison 4 Catheter-directed thrombolysis versus control, Outcome 9 Leg ulceration
(intermediate).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 4 Catheter-directed thrombolysis versus control
Outcome: 9 Leg ulceration (intermediate)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Enden 2011 0/90 0/99 Not estimable
0.01 0.1 1 10 100
favours thrombolysis favours anticoagulation
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Analysis 4.10. Comparison 4 Catheter-directed thrombolysis versus control, Outcome 10 Complete clot
lysis (intermediate).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 4 Catheter-directed thrombolysis versus control
Outcome: 10 Complete clot lysis (intermediate)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Elsharawy 2002 13/18 2/17 41.5 % 6.14 [ 1.62, 23.28 ]
Enden 2011 68/90 56/99 58.5 % 1.34 [ 1.08, 1.65 ]
Total (95% CI) 108 116 100.0 % 2.52 [ 0.52, 12.17 ]
Total events: 81 (Thrombolysis), 58 (Standard anticoagulant)
Heterogeneity: Tau2 = 1.09; Chi2 = 5.62, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours anticoagulation favours thrombolysis
Analysis 4.11. Comparison 4 Catheter-directed thrombolysis versus control, Outcome 11 Complete clot
lysis (late).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 4 Catheter-directed thrombolysis versus control
Outcome: 11 Complete clot lysis (late)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Enden 2011 (1) 68/86 61/86 1.11 [ 0.94, 1.33 ]
0.001 0.01 0.1 1 10 100 1000
favours anticoagulation favours thrombolysis
(1) Four patients had inconclusive results and not reported.
90Thrombolysis for acute deep vein thrombosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.12. Comparison 4 Catheter-directed thrombolysis versus control, Outcome 12 Normal venous
function (intermediate).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 4 Catheter-directed thrombolysis versus control
Outcome: 12 Normal venous function (intermediate)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elsharawy 2002 13/18 2/17 14.2 % 6.14 [ 1.62, 23.28 ]
Enden 2011 29/90 13/99 85.8 % 2.45 [ 1.36, 4.42 ]
Total (95% CI) 108 116 100.0 % 2.98 [ 1.75, 5.08 ]
Total events: 42 (Thrombolysis), 15 (Standard anticoagulant)
Heterogeneity: Chi2 = 1.55, df = 1 (P = 0.21); I2 =35%
Test for overall effect: Z = 4.01 (P = 0.000060)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours anticoagulation favours thrombolysis
Analysis 4.13. Comparison 4 Catheter-directed thrombolysis versus control, Outcome 13 Recurrent VTE
(intermediate).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 4 Catheter-directed thrombolysis versus control
Outcome: 13 Recurrent VTE (intermediate)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Enden 2011 10/90 18/99 0.61 [ 0.30, 1.25 ]
0.01 0.1 1 10 100
favours thrombolysis favours anticoagulation
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Analysis 4.14. Comparison 4 Catheter-directed thrombolysis versus control, Outcome 14 Recurrent VTE
(late).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 4 Catheter-directed thrombolysis versus control
Outcome: 14 Recurrent VTE (late)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Enden 2011 13/87 21/89 0.63 [ 0.34, 1.18 ]
0.01 0.1 1 10 100
favours thrombolysis favours anticoagulation
Analysis 4.15. Comparison 4 Catheter-directed thrombolysis versus control, Outcome 15 Mortality (late).
Review: Thrombolysis for acute deep vein thrombosis
Comparison: 4 Catheter-directed thrombolysis versus control
Outcome: 15 Mortality (late)
Study or subgroup Thrombolysis
Standard
anticoagu-
lant Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Enden 2011 3/90 9/98 0.36 [ 0.10, 1.30 ]
0.1 0.2 0.5 1 2 5 10
favours thrombolysis favours anticoagulation
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A D D I T I O N A L T A B L E S
Table 1. Level of affected leg veins in included studies
Study Potential levels of leg vein included
Arneson 1978 proximal to calf
Common 1976 not specified
Elliot 1979 proximal
Elsharawy 2002 femoral and iliofemoral
Enden 2011 pelvic, iliofemoral, femoral
Goldhaber 1990 popliteal or more proximal
Goldhaber 1996 proximal
Kakkar 1969 not specified
Kiil 1981 not specified
Marder 1977 calf up to iliac vein
Schulman 1986 calf vein thrombosis only
Schweizer 1998 not specified
Schweizer 2000 popliteal or more proximal
Tsapogas 1973 not specified
Turpie 1990 proximal
Ugurlu 2002 popliteal up to inferior vena cava
Verhaeghe 1989 popliteal or more proximal
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MESH DESCRIPTOR Thrombosis 1211
#2 MESH DESCRIPTOR Thromboembolism 880
#3 MESH DESCRIPTOR Venous Thromboembolism 221
#4 MESHDESCRIPTOR Venous Thrombosis EXPLODE ALL
TREES
1979
#5 (thrombus* or thrombopro* or thrombotic* or thrombolic*
or thromboemboli* or thrombos* or embol*):TI,AB,KY
16407
#6 MESH DESCRIPTOR Pulmonary Embolism EXPLODE
ALL TREES
719
#7 (PE or DVT or VTE):TI,AB,KY 4294
#8 ((vein* or ven*) near thromb*):TI,AB,KY 5939
#9 (blood near3 clot*):TI,AB,KY 2358
#10 (pulmonary near3 clot*):TI,AB,KY 5
#11 (lung near3 clot*):TI,AB,KY 4
#12 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR
#9 OR #10 OR #11
21211
#13 MESH DESCRIPTOR Thrombolytic Therapy EXPLODE
ALL TREES
1512
#14 MESH DESCRIPTOR Fibrinolytic Agents EXPLODE ALL
TREES
10655
#15 MESHDESCRIPTOR Fibrinolysis EXPLODE ALL TREES 930
#16 MESH DESCRIPTOR Plasminogen Activators EXPLODE
ALL TREES
2193
#17 (plasminogen near2 activator* ):TI,AB,KY 3444
#18 (tPA or t-PA or rtPA or rt-PA):TI,AB,KY 1961
#19 (thromboly* or fibrinoly* or antithrombotic or antithrombic)
:TI,AB,KY
8330
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(Continued)
#20 (recanalis* or recanaliz*):TI,AB,KY 836
#21 (((clot* or thrombus) near3 (lyse or lysis or dissolve* or disso-
lution))):TI,AB,KY
663
#22 urokinase:TI,AB,KY 774
#23 alteplase :TI,AB,KY 601
#24 reteplase:TI,AB,KY 109
#25 tenecteplase:TI,AB,KY 142
#26 saruplase:TI,AB,KY 33
#27 anistreplase:TI,AB,KY 156
#28 monteplase:TI,AB,KY 14
#29 streptokinase:TI,AB,KY 1276
#30 staphylokinase:TI,AB,KY 17
#31 (avelizin or awelysin):TI,AB,KY 0
#32 (celiase or distreptase or Kabikinase or kabivitrum):TI,AB,KY 12
#33 (Streptase or streptodecase or apsac or Abbokinase or renoki-
nase ):TI,AB,KY
110
#34 (Actilyse or Activase or Eminase or Retavase or Rapilysin or
desmopletase or u-pa or alfimeprase ):TI,AB,KY
85
#35 (streptodornase ):TI,AB,KY 50
#36 (pro?urokinase or rpro?uk ):TI,AB,KY 44
#37 (lumbrokinase or duteplase or lanoteplase or pamiteplase):TI,
AB,KY
44
#38 #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR
#20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR
#27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR
#34 OR #35 OR #36 OR #37
17883
#39 #12 AND #38 5255
#40 * NOT SR-PVD:CC AND 31/05/2013 TO 31/01/2016:DL 231856
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(Continued)
#41 #39 AND #40 1054
WH A T ’ S N E W
Last assessed as up-to-date: 25 February 2016.
Date Event Description
25 February 2016 New search has been performed Search updated. No new included studies. New data
from previously included study added. Seven new stud-
ies excluded. Two new ongoing studies added
25 February 2016 New citation required but conclusions have not
changed
Search updated. No new included studies. Seven new
studies excluded. Two new ongoing studies added.
New data from previously included study added. Text
amended to reflect current Cochrane policy. ’Summary
of findings’ table added
H I S T O R Y
Protocol first published: Issue 4, 2000
Review first published: Issue 4, 2004
Date Event Description
6 June 2013 New citation required but conclusions have not
changed
New search carried out. New author joined the review
team. One new study included, four previously ex-
cluded studies now included.One new study excluded.
Risk of bias assessed for all included studies and text
updated. No change to conclusions
6 June 2013 New search has been performed One new study included, four previously excluded
studies now included. One new study excluded
11 November 2009 Amended Some graph labels changed and minor edits made to
the text.
3 November 2008 Amended Converted to new review format.
96Thrombolysis for acute deep vein thrombosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
12 November 2007 New search has been performed Four additional excluded studies added. Dates of
searches updated. Plain Lanugage Summary provided
by theCochraneConsumerNetwork added and edited
by author. Minor copy edits throughout text.. Analy-
ses graphs copy edited for uniformity in presentation.
Technical edits performed to clarify outcome statistics.
Conclusions remain unchanged
C O N T R I B U T I O N S O F A U T H O R S
LW: assessed reference list, extracted data, updated review text
CB: assessed reference list, extracted data, updated review text
MPA: updated review text, resolved differences where required
D E C L A R A T I O N S O F I N T E R E S T
LW: has declared that she received travel and accomodation fees from the European Society of Angiology for speaking at the 2012
meeting on this topic
CB: CB is a member of Cochrane Vascular’s editorial base staff. Where appropriate, editorial tasks were carried out by other group
members
MPA: none known
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• Chief Scientist Office, Scottish Government Health Directorates, The Scottish Government, UK.
The Cochrane Vascular editorial base is supported by the Chief Scientist Office.
• National Institute for Health Research (NIHR), UK.
This project was supported by the NIHR, via a Cochrane Programme Grant funding (13/89/23) to Cochrane Vascular. The views
and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme,
NIHR, NHS or the Department of Health.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
After consideration, the review authors decided to increase the inclusion period of acute symptoms of DVT from 14 to 21 days as this
is more commonly used in recent studies. Trials previously excluded due to this were reassessed and included.
In the initial published version, the quality of the trials was investigated using the methods of Jadad (Jadad 1996) and Schulz (Schultz
1995). In keeping with updated Cochrane Collaboration requirements, quality has now been assessed using the Cochrane risk of bias
tool (Higgins 2011).
For the 2016 update we changed the time point definitions to differentiate late outcomes after five years as two studies (Arneson 1978;
Enden 2011) now reported results within this period. Due to this Arneson 1978 data was re-categorised from intermediate to late.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anticoagulants [therapeutic use]; RandomizedControlledTrials as Topic; Thrombolytic Therapy [adverse effects; ∗methods]; Treatment
Outcome; Varicose Ulcer [prevention & control]; Venous Thrombosis [complications; ∗drug therapy]
MeSH check words
Humans
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